-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, S7PXDZysWABrezMs6D0rMWOcoJjpscf3V9u5AkMXjn8XtIxWnnHHhTHYhbwoLPSq RHIO/jVRA/ZQkyuRrBXYBg== 0000801748-04-000003.txt : 20040325 0000801748-04-000003.hdr.sgml : 20040325 20040325145217 ACCESSION NUMBER: 0000801748-04-000003 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20031231 FILED AS OF DATE: 20040325 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEMACARE CORP /CA/ CENTRAL INDEX KEY: 0000801748 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 953280412 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-15223 FILM NUMBER: 04689497 BUSINESS ADDRESS: STREET 1: 21101 OXNARD STREET CITY: WOODLAND HILLS STATE: CA ZIP: 91367 BUSINESS PHONE: 818-226-1968 MAIL ADDRESS: STREET 1: 21101 OXNARD STREEET CITY: WOODLAND HILLS STATE: CA ZIP: 91367 10-K 1 hc10k03.txt FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2003 ======================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) /X/ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2003 / / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _____________ Commission file number: 0-15223 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California 95-3280412 (State or other jurisdiction (I.R.S. Employer of incorporation or Identification Number) organization) 21101 Oxnard Street Woodland Hills, California 91367 (Address of principal (Zip Code) executive offices) Registrant's telephone number, including area code: (818) 226-1968 Securities registered pursuant to Section 12(b) of the Act: None Securities registered pursuant to Section 12(g) of the Act: Common Stock (without par value) Rights to purchase Preferred Stock Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: /x/ YES ___ NO Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K / / The aggregate market value of the Common Stock held by non-affiliates of the Registrant as of June 30, 2003, the last business day of the Registrant's most recently completed second fiscal quarter (based upon the closing bid price of the Common Stock as reported by the OTC Bulletin Board) was approximately $6,452,401. Indicate by check mark whether the Registrant is an accelerated filer (as defined in Rule12b-2 of the Act). / / YES /x/ NO As of March 23, 2004, 7,756,060 shares of Common Stock of the Registrant were issued and outstanding. DOCUMENTS INCORPORATED BY REFERENCE Portions of the Registrant's definitive proxy statement relating to its 2004 annual meeting of shareholders, which will be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days of the close of the Registrant's last fiscal year, are incorporated by reference into Part III of this Report. =========================================================================== TABLE OF CONTENTS PART I Page Number ------ Item 1. Business General............................................. 1 Recent Developments................................. 1 Blood Products Operations........................... 3 Blood Services Operations........................... 3 Competition......................................... 4 Sales to Major Customers............................ 5 Marketing........................................... 5 Human Resources..................................... 5 Suppliers........................................... 5 Government Regulation............................... 6 Professional and Product Liablity Insurance......... 7 Additional Information.............................. 7 Item 2. Properties.......................................... 8 Item 3. Legal Proceedings................................... 8 Item 4. Submission of Matters to a Vote of Security Holders. 8 PART II Item 5. Market for Registrant's Common Equity and Related Stockholder Matters......................... 8 Item 6. Selected Financial Data............................. 9 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations................. 10 Item 7a. Quantitative and Qualitative Disclosures about Market Risk......................................... 23 Item 8. Financial Statements and Supplementary Data......... 23 Item 9. Changes and Disagreements with Accountants on Accounting and Financial Disclosures................ 24 Item 9A. Controls and Procedures............................. 24 PART III Item 10. Directors and Executive Officers of the Registrant. 24 Item 11. Executive Compensation............................. 24 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters..... 25 Item 13. Certain Relationships and Related Transactions..... 25 Item 14. Principal Accountant Fees and Services............. 25 PART IV Item 15. Exhibits, Financial Statement Schedules and Reports on Form 10-K............................... 25 Signatures................................................... 27 Index to Consolidated Financial Statements and Schedules..... F-1 i 1 PART I Item 1 Business - ------ -------- This 2003 Annual Report on Form 10-K contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward- looking statements (See "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations - Risk Factors"). The Company does not undertake to update its forward-looking statements to reflect actual events and outcomes or later events. General - ------- HemaCare Corporation ('HemaCare" or the "Company") collects, processes and distributes blood products to hospitals in the United States. Additionally, the Company provides blood related services principally therapeutic apheresis procedures, stem cell collection and other blood treatments to patients with a variety of disorders. Blood related services are usually provided on an "in-patient" basis under contract with the hospital as an outside purchased service. The Company has operated in Southern California since 1979. In 1998, the Company expanded operations to include portions of the eastern U.S. In 2003, new management completed a comprehensive evaluation of the Company's operations, and at the conclusion of this review, developed a restructuring plan to reduce the number of geographic areas served, reduce the overhead costs associated with supporting the organization, and improve the collection capability in the geographic areas still served by the Company. Management's strategy is to return the Company to a profitable foundation before exploring opportunities for growth in other geographic areas or into new lines of business. The implementation of this plan started in the third quarter of 2003, and continued into early 2004. Management remains focused on completing the implementation of the restructuring plan, and improving the profitability of the remaining operations including growth within existing geographic markets, expanding therapeutic apheresis market share and exploring new customer opportunities such as research companies. Although most blood suppliers are organized as not-for-profit, tax- exempt organizations, all suppliers charge fees for blood products to cover their costs of operations. The Company believes that it is the only investor-owned and taxable organization operating as a blood supplier with significant operations in the U.S. Recent Developments - ------------------- Implementation of Restructuring Plan As the result of an evaluation of the overall operations of the Company, management identified several non-performing donor centers that hindered the Company's ability to produce profitable results. In 2002 and 2003, these donor centers produced operating losses $553,000 and $733,000 respectively. In the third quarter of 2003, management implemented a plan to cease operations at these donor centers, as well as the mobile operations associated with these centers. The donor centers closed included Albany, New York; Chicago, Illinois; three centers in North Carolina; and Williston, Vermont. As of December 31, 2003, all of these centers had been closed with the exception of one center in North Carolina, which was closed in January 2004. The costs associated with the closure of these centers are reflected in the Company's 2003 results in accordance with generally accepted accounting principles. These expenses include the write-off of certain assets previously used in the operations of the closed donor centers, severance payments to terminated employees, recognition of unexpired facility lease obligations, and other associated costs. 1 2 Limitation on Blood Product Supply Blood products organizations, as well as regulatory agencies, focus significant attention and resources on improving the safety of the blood supply. Requirements to screen potential donors for possible exposure to a variety of pathogens, including HIV, malaria and SARS, have reduced the pool eligible donors. In addition, regulations and industry standards require an increasing number of tests on donated blood products to detect pathogens, including a new bacterial detection quality control test, which may impact expiration rates of platelet products. The Company faces an increasing risk that these factors will increase the cost of producing blood products and reduce the ability to generate a sufficient supply of blood products to satisfy customer demand. The inability to satisfy customer demand could result in the loss of customers, and a loss of revenue. Termination of California Exemption Since 1976, California law has prohibited the transfusion of blood products to patients if the donors of those products were paid unless, in the opinion of the recipient's physician, blood from a non-paid donor was not immediately available. Apheresis platelet products obtained from paid donors were exempted from this law by a series of state statutes, the latest of which expired on January 1, 2003. Consequently, HemaCare no longer offers cash compensation to apheresis platelet donors. In 2003, the Sherman Oaks apheresis donor program provided revenue of $4.1 million compared with $5.4 million in 2002. Although the termination of the apheresis platelet exemption has impacted platelet collections at the Sherman Oaks facility, the impact, although not immaterial, has been less than expected. The Company has no indication that it cannot maintain a substantial donor base on a voluntary basis. Nursing Shortage Multiple factors, including a decline in nursing graduates, the retirement or movement of experienced nurses out of direct patient care, and the January 1, 2004 California law that increased the nurse to patient staffing ratios, have created a nursing shortage. This shortage has directly affected the blood industry because certain regulations and industry standards require a nurse's presence during donation and for therapeutic apheresis procedures. The shortage of nurses has increased the cost of recruitment and retention of nursing staff and may limit the Company's ability to provide and expand operations. This challenge of locating qualified nurses, however, may provide additional opportunities as hospitals may choose to outsource therapeutic services to HemaCare. If HemaCare can succeed in recruiting qualified nurses to perform these therapeutic services, the potential market for such services could increase in the future. Settlement of ARC litigation In the fourth quarter of 2002, the Company settled the anti-trust litigation with the American Red Cross ("ARC"). The Company contended that the ARC was capitalizing on its position as the dominant blood supplier in the U.S. and bundling products and services to prevent or eliminate competition in the blood industry. Pursuant to the terms of the settlement, the ARC has agreed not to bundle blood-related products and services in the New England or the Carolinas regions in a manner that would constrain lawful competition. In addition, litigation with the ARC relating to what the Company believed to be anticompetitive business practices in California was settled without the payment of cash to either party. Other In October 2003, Robert S. Chilton was appointed the Company's Executive Vice President and Chief Financial Officer, succeeding David Fractor who left the Company in June 2003. 2 3 Blood Product Operations - ------------------------ The practice of modern medicine depends on the availability of a safe and adequate blood supply. Most blood product collections consist of single units of whole blood. The actual collection process is simple and safe for the donor. After collection, whole blood units are tested and processed into components, and then distributed to hospitals for transfusion. These components include red blood cells, plasma and platelets. All blood products have limited therapeutic lives. Apheresis collection separates blood components during the donation process through the use of a cell separator. This process allows for the collection of only the desired components of a donor's blood and returns the other blood components to the donor's blood stream. Apheresis blood product collection, used by HemaCare to collect platelets, is considerably more complex and more expensive than whole blood collection and processing. However, platelets collected from a single donor are considered more desirable because platelet products collected from multiple whole blood donors increases the risk of exposing the recipient to blood born pathogens. Automated apheresis equipment is costly and requires longer donation times which result in higher labor costs. The complexity of the donation process, and longer donation time makes recruiting donors for apheresis procedures more difficult than recruiting whole blood donors. On average, only 5% of the United States population donates blood and a much smaller percentage are apheresis platelet donors. Recruiting and retaining donors is critical to the success of blood product operations. Apheresis platelet donors are recruited from the most dedicated and committed subset of the whole blood donor population. On average, such donors donate platelets between four and six times a year, compared to twice a year for whole blood donors. Generally, success in donor recruitment is a major factor in success of any blood collection program. The Company has demonstrated a consistent track record of donor recruitment for both whole blood and apheresis donors at the donor centers it currently operates. Product safety is of paramount concern when dealing with blood products. The U.S. Food and Drug Administration ("FDA") is the agency principally responsible for the regulation of the blood products industry in the U.S. The Company's blood product operations are either licensed or registered with the FDA and are regularly inspected by FDA personnel. Additionally, the Company's operations are licensed, regulated and inspected by various state agencies. The American Association of Blood Banks ("AABB") is the blood industry sponsored organization responsible for maintaining and improving science, safety, quality and education relating to blood. The Company is an institutional member, and the Company's operations are accredited by the AABB. The Company has blood collection operations in four states, principally in Southern California and in New England. Some of these operations are hospital-based collection centers, but the Company also operates several free standing blood collection centers, as well as mobile blood collection operations. Blood Services Operations - ------------------------- Therapeutic apheresis is a technique for removing harmful components from a patient's blood and is used in the treatment of autoimmune diseases and other disorders. Therapeutic services are provided upon the request of a hospital, which has received an order from a patient's physician. Therapeutic treatments are administered using mobile equipment operated at the patient's bedside or in a hospital outpatient setting. The mobile therapeutic equipment includes a blood cell separator and the disposables needed to perform the procedure. Treatments are administered by trained, nurse-specialists, under the supervision of a specially trained physician, and acting in accordance with documented operating procedures and quality assurance protocols based on guidelines developed by the AABB and the Joint Commission on Accreditation of Healthcare Organizations ("JCAHO"). 3 4 Since requests for therapeutic apheresis treatments are often sporadic and unpredictable, many hospitals choose not to equip, staff and maintain an apheresis unit. The existing nurse shortage in the U.S. has also hindered hospital efforts to adequately staff apheresis units. The Company's services enable hospitals to offer therapeutic apheresis services to their patients on an "as needed" basis without incurring the costs associated with maintaining a full-time team of apheresis specialists. In addition, the Company's services can serve to supplement a hospital's existing apheresis capability when demand exceeds capacity. Blood services revenue depends on a number of factors, including the occurrence of disease states that are appropriately treated by these services, and the perceived benefits of blood therapies compared to alternative courses of treatment. The Company believes that education on the benefits of therapeutic apheresis results in increases in the application of such treatments in medically appropriate circumstances. The Company's affiliated medical directors conduct educational seminars for physicians to inform them of the benefits of therapeutic apheresis relative to other modes of patient treatment. The Company provides therapeutic services using all currently recognized treatment methods: plasma exchange and cell depletion; in- line immunoadsorbant columns; stem cell collection, and photopheresis. Since its inception, the Company has performed approximately 67,000 therapeutic apheresis procedures. Patients suffering from diseases such as multiple myeloma, polyneuropathy, leukemia, systemic lupus erythematosus, scleroderma, hyperviscosity syndrome, thrombocytosis, thrombotic thrombocytopenic purpura (TTP), myasthenia gravis and Guillain-Barre syndrome may benefit from therapeutic apheresis treatments. The Company provides therapeutic apheresis services on a regional basis in a total of seven states. Major operations are located in Los Angeles and New York. Competition - ----------- General Most U.S. blood suppliers are organized as not-for-profit, tax-exempt entities. However, all blood suppliers finance their activities by charging fees to hospitals for the products they utilize. These fees are generally set at levels based on the supply and demand for specific products, and are influenced by the potential competition from other blood suppliers. Many suppliers have greater financial, technical and personnel resources than the Company. In addition, since many of the Company's competitors are tax-exempt, they do not bear the tax burden that the Company faces, and they have access to lower cost tax-exempt debt financing. Their status as charitable institutions may give them an advantage in recruiting volunteer donors. The Company competes on the basis of responsiveness to customer needs, value-based pricing and the high quality of the services and products provided. Blood Products In the United States, approximately 50% of all blood products are supplied by the ARC's national collection network. Approximately 40% of all blood products are supplied by local and regional blood centers, including the Company. The remainder is collected by hospitals directly. The Company competes in the marketplace through a strategy of offering blood product supply programs tailored to the requirements of individual customers. The Company consistently reevaluates and revises its product supply programs to respond to marketplace factors. Some competitors have advantages over the Company as a result of established positions and relationships within the communities they serve. In addition, the ARC's size and market dominance provides them with greater resources to sustain periods of unprofitable sales, or to adopt aggressive pricing strategies for the purpose of defending or increasing market share. 4 5 Blood Services The competition in the therapeutic blood services business is primarily regional and community blood banks, dialysis companies that also provide therapeutic blood services, and a wide range of small blood services companies. In addition, since some diseases treatable with therapeutic apheresis are also treatable by other medical therapies, the competition for the Company's blood services business also include companies that market or provide any of these competing medical therapies. The Company believes that it competes in this market by offering highly trained and experienced nurses and greater availability for customers with immediate needs. In addition, the Company provides education to the medical community on the benefits of therapeutic apheresis as a treatment solution for various diseases. Sales to Major Customers - ------------------------ During 2003, 2002 and 2001, no single customer accounted for more than 10% of our total revenue. Marketing - --------- The Company's marketing programs include a combination of medical education, advertising and promotional programs, in-person sales and other marketing programs directed to selected physicians and hospitals. The Company markets its products and services in the form of supply programs that meet the specific needs of individual customers. As a smaller company than the main competitors in the marketplace, HemaCare can offer far more flexibility in supply arrangements and pricing structure. This flexibility and focus on customer service are the main messages communicated throughout all the marketing vehicles the Company utilizes. Human Resources - --------------- As of February 26, 2004, the Company had 270 employees, including 96 part-time employees. Most of the Company's professional and management personnel possess prior experience in hospitals, medical service companies or blood banks. None of the Company's employees are represented by a labor union. The Company considers its relations with its employees to be good. As part of management's restructuring plan, the Company terminated 29 employees who principally were employed in the closed donor centers. Severance payments of approximately $77,000 were paid to these employees upon their termination. Suppliers - --------- The Company maintains relationships with numerous suppliers who provide cell separator equipment, disposable supplies, replacement fluids, testing services and blood products. Generally, the Company has not experienced difficulty in obtaining most of its equipment and supplies; however, if there were material adverse changes in the sources of its supplies, the Company's operations could be adversely affected. In particular, in the event of a war or other international conflict, the availability of critical supplies could be negatively affected and the cost of procuring these supplies could increase. The Company relies on blood donors to provide the platelets and whole blood required to produce the blood products manufactured and sold by the Company. The Company competes with the ARC and other blood suppliers in recruiting its volunteer donors. The growth of the 5 6 Company's manufactured blood products business is dependent on the Company's ability to attract, screen and retain qualified donors. Albumin is the most commonly used replacement fluid in therapeutic apheresis procedures. In late 1996, a shortage of albumin arose when a major U.S. manufacturer was required by regulatory agencies to temporarily cease operations. As a result of the shortage, the price of albumin to HemaCare more than doubled. After 1998, the supply of albumin increased and prices declined. However, in the event of a war, the supply of albumin could be limited and the price would be expected to increase. Government Regulation - --------------------- Blood Product Operations All hospitals and blood suppliers are subject to extensive regulation by the FDA and various state licensing authorities. FDA regulations are comprehensive, complex and extend to virtually all aspects of the blood supply industry, including: recruiting; screening blood donors; processing, testing, labeling, storing and shipping blood products; recordkeeping; and communications with hospital customers and donors. In addition, FDA regulations also extend to the manufacturers of all critical supplies and equipment used in the blood supply industry. The Company views blood product safety and compliance with governmental regulations as paramount concerns at all times. The Company has developed extensive procedures and internal quality control programs to increase compliance with all governmental regulations and industry standards. Employees routinely participate in training classes. Employees are tested at the conclusion of these classes to insure that the desired level of understanding of the Company's compliance and safety procedures is achieved. Finally, HemaCare's Regulatory Affairs and Quality Assurance Department conducts periodic audits of each operating unit to identify the level of compliance with regulatory procedures. During 2003, the FDA conducted inspections at each of HemaCare's facilities. The Company dedicated substantial resources to provide the FDA with all the information requested to complete each inspection. At the conclusion of each inspection, the FDA provided the Company with a list of observations of regulatory issues. The Company believes it has adequately addressed all of the issues raised by the FDA, and that it is in compliance with current FDA regulations. During the past year, representatives from the Department of Health for the State of California have conducted an audit of the Company's operations located in Whittier, California. This audit focused on compliance with specific California laws that cover HemaCare's operations. At the conclusion of this audit, the Department of Health provided the Company with a list of observations that have since been addressed. The Company believes that it is in compliance with California regulations governing the Company's operations within the state. Organizations within the blood supply industry are registered by the FDA to operate blood collection and/or blood processing facilities. All of the Company's facilities operate under an FDA registration, with the exception of the Company's operations in Whittier, California. In this instance, the Company operates a blood collection facility within a hospital and does so under the hospital's FDA registration. The FDA also issues licenses to organizations within the blood supply industry to ship blood products across state lines if the qualifying organization can demonstrate adequate employee training programs, procedure documentation and quality control systems to insure the quality of the products shipped. HemaCare holds a license for its Sherman Oaks, California facility to ship selected blood products across state lines. The Company has submitted an expanded license request to the FDA for additional blood products manufactured at Sherman Oaks. This request is pending with the FDA. In December 2003, the FDA approved the Company request to license the Scarborough, Maine facility for platelets and other products drawn on the Trima component collection machine manufactured by Gambro BCT, expanding this facility's licensed product line. 6 7 Other Matters State and federal laws set forth anti-kickback and self-referral prohibitions, and otherwise regulate financial and referral relationships between blood suppliers, hospitals, physicians and others in the blood supply industry. The Company believes its present operations comply with all currently applicable regulations in this area. Joshua Levy, M.D., the national medical director of the Company and a shareholder, through his private practice in Sherman Oaks, California, treats patients who require therapeutic services. Sales by the Company to hospital customers for therapeutic services provided to Dr. Levy's patients amounted to approximately 2%, or less, of the Company's total revenues in each of the three years ended December 31, 2003. There are no agreements between Dr. Levy and the Company's hospital customers that require the hospitals to select HemaCare to provide therapeutic services to Dr. Levy's patients. New health care related regulations are continuously under consideration by lawmakers at the federal level, and in many of the individual states in where the Company currently operates. Many of these new regulations could have a direct impact on the Company and its operations. The Company is not aware of any specific proposed regulation that would have a material adverse impact on the Company; however, the Company is uncertain what changes may be made in the future regarding health care policies, especially those regarding hospital reimbursements, health insurance coverage and managed care that may materially impact the Company's operations. Professional and Product Liability Insurance - -------------------------------------------- The blood product and blood services business inherently is subject to substantial potential liabilities for personal injury claims. The Company maintains medical professional liability insurance in the amount of $3,000,000 for a single occurrence and $5,000,000 in the aggregate per year in California, and $1,000,000 for a single occurrence and $3,000,000 in the aggregate per year in other states. There can be no assurance that potential insurance claims will not exceed present coverage or that continued or additional insurance coverage would be available at affordable premium costs. If such insurance were ineffective or inadequate for any reason, the Company could be exposed to significant liabilities. Additional information - ---------------------- The Company makes available free of charge through its website, www.hemacare.com, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) of the Securities Exchange Act of 1934, as soon as practical after those reports are filed with the Securities and Exchange Commission (the "SEC"). The Company's filings may also be read and copied at the SEC's Public Reference Room at 450 Fifth Street, NW, Washington D.C. 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at 800-SEC-0330. The SEC also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that site is www.sec.gov. Item 2 Properties - ------ ---------- In January 2003, the Company reduced the square footage of its Sherman Oaks, California facility from 12,000 square feet to approximately 6,300 square feet. The Company operates an apheresis donor center, a laboratory, a manufacturing facility for whole blood components and a distribution center at this location. The Company is currently renting the space on a month-to-month basis for a monthly amount of approximately $15,500 while negotiating a lease for a multi-year term. 7 8 The Company's corporate offices and part of its distribution center are located in an 11,250 square foot facility in Woodland Hills, California. The rent is fixed at $16,200 per month and the lease on this space expires October 31, 2006. The Company has one five-year option to extend the lease on this space at the then current market price. The Company leases space for a donor center in a 3,600 square foot facility in Scarborough, Maine. The monthly rent is approximately $6,000 per month, with an escalation clause for changes in the Consumer Price Index. The lease term expires October 31, 2004. The Company has the option to extend the lease for two additional five-year terms at rates adjusted for changes in the Consumer Price Index. The Company also leases space for a donor center in a 2,500 square foot facility in Bangor, Maine. The monthly rent is approximately $3,900 per month. The lease term expires December 31, 2006, and the Company has the option to extend the lease for two additional five-year terms at rates adjusted for changes in the Consumer Price Index. In addition, the Company leases a 1,278 square foot office space in Yonkers, New York which expires August 31, 2006, and leases an apartment in Yonkers, New York which expires July 1, 2004. Finally, the Company occupies space on the campus of several of its client hospitals. While the arrangements vary, certain of these facilities are formally subject to a lease agreement with the sponsoring hospital for periods concurrent with the blood supply agreement. Other agreements grant the Company the right to utilize space and facilities on the hospital premises during the term of the blood supply agreement at no cost. Item 3 Legal Proceedings - ------ ----------------- From time to time, the Company is party to various claims, actions and proceedings incidental to its normal business operations. The Company believes there is sufficient insurance coverage, or that the outcome of such claims, actions and proceedings, individually and in the aggregate, will not have a material adverse effect on the business and financial condition of the Company. Item 4 Submission of Matters to a Vote of Security Holders - ------ ---------------------------------------------------- None. PART II Item 5 Market for Registrant's Common Equity and Related Stockholder Matters - ------- ------------------------------------------------------- Effective November 2, 1998, the Company's Common Stock became quoted on the OTC Bulletin Board under the symbol HEMA. Prior to that date, the Company's Common Stock was listed on the Nasdaq Small Cap Market ("Nasdaq") under the same symbol. The following table sets forth the range of high and low closing bid prices of the Common Stock, as reported by the OTC Bulletin Board, for the periods indicated. These prices reflect inter-dealer quotations, without retail markups, markdowns or commissions, and do not necessarily represent actual transactions. The prices appearing below were obtained from the National Quotation Bureau. 8 9 2003 2002 --------------- --------------- Quarter ended High Low High Low ---------------- ------ ----- ----- ----- March 31 $0.66 $0.42 $1.65 $0.95 June 30 $0.95 $0.58 $1.38 $0.97 September 30 $1.20 $0.63 $0.96 $0.45 December 31 $0.97 $0.63 $0.60 $0.27 On March 4, 2004, the last reported sales price for the Company's Common Stock was $0.64. Shareholders are urged to obtain current market quotations for the Company's Common Stock. The Company intends to retain any future earnings for use in its business, and therefore, does not anticipate declaring or paying any cash dividends in the foreseeable future. Additionally, the Company's line of credit prohibits the payment of dividends. The declaration and payment of any cash dividends in the future will depend upon the Company's earnings, financial condition, capital needs, line of credit requirements and other factors deemed relevant by the Board of Directors. On March 4, 2004, the approximate number of shareholders of record was 300 (excluding individual participants in nominee security position listings). Item 6 Selected Financial Data - ------ ------------------------ The following selected financial data should be read in conjunction with the other information and financial statements, including the notes thereto, appearing elsewhere herein:
Years Ended December 31, (In Thousands, except Per Share Data) 2003 2002 2001 2000 1999 ------- ------- -------- ------- ------- Revenue........................ $27,488 $27,817 $25,199 $21,512 $19,021 Gross profit................... 2,251 3,745 4,409 4,850 4,026 Income (loss) from operations.. (1,695) (329) 491 1,358 1,085 Write off of impaired goodwill. - (362) - - - Provision (benefit) for income taxes........................ 2,984 (151) 190 (2,901) 28 Net income (loss).............. $(4,679) $ (591) $ 323 $ 4,350 $ 1,057 Basic per Share Amounts: - ------------------------ Income (loss) from operations.. $ (0.22) $ (0.04) $ 0.07 $ 0.18 $ 0.15 Net income (loss).............. $ (0.60) $ (0.08) $ 0.04 $ 0.57 $ 0.14 Diluted Per Share Amounts: - -------------------------- Income (loss) from operations.. $ (0.22) $ (0.04) $ 0.06 $ 0.16 $ 0.13 Net income (loss).............. $ (0.60) $ (0.08) $ 0.04 $ 0.50 $ 0.13 Total assets................... $ 8,286 $13,455 $13,082 $11,477 $ 7,574 Long-term debt and capital lease obligations, net of current portion............... $ 1,078 $ 1,353 $ 802 $ 46 $ 541 Shareholders' equity........... $ 3,411 $ 8,087 $ 8,427 $ 8,203 $ 4,440
9 10 Item 7 Management's Discussion and Analysis of Financial Condition and Results of Operations - ------ -------------------------------------------------- General - ------- HemaCare operates two primary business segments. The first is the blood products segment which supplies hospitals and other customers with whole blood, apheresis platelets and other blood products. The Company operates and manages donor centers and mobile donor vehicles to collect blood products from donors. The blood products segment has undergone several significant changes during the past year. First, after a thorough evaluation of this business segment, management implemented a plan to restructure the operations of this segment to return the segment to profitability. This plan included closing several donor centers, including the mobile operations associated with these centers. Management implemented this plan in the third quarter of 2003, closing four centers in Albany, New York; Chicago, Illinois; Raleigh, North Carolina; and Williston, Vermont. The Company continued with the implementation of the restructuring plan in the fourth quarter of 2003 with the closure of the donor center in Durham, North Carolina. The completion of the restructuring plan occurred in January 2004 with the closure of the donor center in Chapel Hill, North Carolina. Another significant event for the blood products segment occurred in early 2003 when California law no longer permitted the transfusion of blood products to patients from paid donors. The Sherman Oaks platelet donor center offered compensation to apheresis donors prior to 2003, and there was considerable concern about the future of this donor center. The Company converted the Sherman Oaks program to a voluntary program in January 2003, and although the program did see a decline in platelet donations, donations increased throughout 2003 to a point nearly equal to levels achieved in late 2002. Other significant events for the blood products segment include increasing staff costs as a result of a growing nursing shortage in the U.S., increases in workers' compensation insurance, increased regulatory requirements to defer potential donors to reduce the risk of pathogens in the blood supply, and industry requirements to test platelet products for bacteria beginning March 2004 which is anticipated to increase the likelihood of product expiration and discards. HemaCare's blood services segment includes therapeutic apheresis procedures, stem cell collection and other blood therapies provided to patients generally in a hospital setting. This segment fluctuates based on the occurance rate of diseases treated with therapeutic apheresis, the degree hospitals have fully staffed apheresis units available, and the degree of success of the Company's efforts in physician education about the potential benefits of therapeutic apheresis as a treatment alternative. Over the past few years, this business segment has been relatively stable in Southern California; however, the Company believes growth opportunities exist in the New York market. The New England market has steadily declined recently due principally to difficulties in recruiting and retaining trained apheresis nurses. Results of Operations - --------------------- The following table sets forth, for the periods indicated, certain items in the statement of operations as a percentage of net revenue and the percentage dollar increase (decrease) of such items from period to period. 10 11
Percentage Dollar Percent of Net Sales Increase (Decrease) Year Ended December 31, Year Ended December 31, ----------------------- ----------------------- 2003 2002 2001 '02 to '03 '01 to '02 ------ ------ ------ ---------- ---------- Revenues..................... 100.0% 100.0% 100.0% -1.2% 10.4% Operating costs.............. 91.8% 86.5% 82.5% 4.8% 15.8% ------ ------ ------ --------- ------- Gross profit................. 8.2% 13.5% 17.5% -39.9% -15.1% General and administrative expenses.................... 14.4% 14.6% 15.5% -3.1% 4.0% ------ ------ ------ --------- ------- Income(loss) from operations. -6.2% -1.1% 2.0% -415.2% -167.0% Other income(expense)........ - -0.2% 0.1% 100.0% -331.8% Write off of impaired goodwill.................... - -1.3% - 100.0% -100.0% Income(loss) before income taxes....................... -6.2% -2.6% 2.1% -128.4% -244.6% Provision (benefit) for income taxes................ 10.9% -0.5% 0.8% 2076.2% -179.0% ------ ------ ----- -------- ------- Net income(loss)............. -17.1% -2.1% 1.3% -691.7% -283.0%
Year ended December 31, 2003 compared to the Year ended December 31, 2002 - --------------------------------------------------------------------- Overview The Company experienced a materially higher net loss in 2003 compared with 2002. The net loss for 2003 was $4,679,000, or $.60 both basic and fully diluted loss per share, compared with a net loss of $591,000, or $.08 both basic and diluted loss per share for 2002. This represents a 692% increase in the loss reported between the two periods. The four main reasons for this result are the decline in therapeutic apheresis procedures, the costs associated with closing blood product operations as part of management's restructuring plan, increased insurance costs, and the increase in the deferred tax asset valuation reserve. Gross profit declined 39.9% to $2,251,000 from $3,745,000 in 2002 primarily due to the decline in therapeutic apheresis procedures, the costs incurred in 2003 associated with management's restructuring plan and increases in insurance costs. The provision for income taxes for 2003 was $2,984,000 compared with a net benefit of $151,000 in 2002. This change reflects the increase in the deferred tax asset valuation reserve in 2003. In addition, ongoing operating losses in the blood products segment prior to the implementation of management's restructuring plan contributed to the net loss in 2003. General and administrative expenses decreased 3.1% in 2003 to $3,946,000 from $4,074,000 in 2002. This is mostly attributable to lower legal expenses in 2003 since the Company settled the ARC litigation in late 2002, and severance expenses in 2002 associated with the termination of the prior Chief Executive Officer. 11 12 Revenue and Gross Profit Blood Services Revenue for 2003 declined $329,000, or 1.2%, compared with 2002. The main reason for this decline in revenue is a 11.4% decline in therapeutic apheresis procedures, principally in the Southern California and New England markets. During 2003, the Company performed 6,328 therapeutic apheresis procedures, whereas 7,140 procedures were performed in 2002. As a result, therapeutic apheresis revenue declined $915,000, or 10.9%, from $8,373,000 to $7,458,000. In turn, this decline in revenue contributed to a 13% decrease in gross profit, from $2,748,000 to $2,390,000. The balance of the decrease in gross profit is mostly attributable to increases in workers' compensation insurance and professional liability insurance costs, especially in California. Blood Products Blood products revenue for 2003 grew $586,000 to $20,030,000 from $19,444,000, representing an increase of 3%. The following table illustrates the components included in blood products revenue for 2003 and 2002, and segregates that portion of blood products revenue associated with the closed centers:
For the tweleve months period ended December 31, ($ in Thousands) Ongoing Centers Closed Centers* California Mobiles Total ----------------- ------------------ ------------------ ------------------ 2003 2002 2003 2002 2003 2002 2003 2002 -------- -------- -------- ------- -------- -------- -------- -------- Revenue.................... $ 9,631 $ 9,640 $ 3,028 $ 3,191 $ 7,371 $ 6,613 $20,030 $19,444 Gross Profit............... $ 511 $ 1,304 $(1,331) $ (553) $ 681 $ 246 $ (139) $ 997 Gross Profit Margin........ 5% 14% (44%) (17%) 9% 4% (1%) 5% Units Sold Single Donor Platelets.. 13,510 17,118 3,433 5,749 - - 16,943 22,867 Whole Blood............. 11,676 9,774 3,060 6,810 29,891 31,897 44,627 48,481 - ------------------
* Includes facility at the University of North Carolina, Chapel Hill that was closed in January 2004. All of the increase in blood products revenue from 2002 to 2003 came from California mobiles, even though the number of whole blood units collected by this business unit actually declined 6.3%. This result was due to increases in prices due to additional pathogen testing and a change in product mix to a higher percentage of leukoreduced red blood cells that garner higher average prices. Ongoing center revenue remained flat between 2003 and 2002. This occurred as sales volume of single donor platelets declined 21.1% and sales of whole blood products increased 19.5%. Single donor platelet volume declined principally from loss of donors at the Sherman Oaks donor center when this center converted to a volunteer program in January 2003. Increases in whole blood sales occurred mostly because of higher volumes from the Maine and Massachusetts donor centers. Closed center revenue declined due mostly to the fact that most of these facilities were closed at the end of the third quarter. Meaning, a direct comparison with all four quarters of 2002 will show a decline in revenue. The gross profit for blood products decreased from $997,000 in 2002 to negative gross profit of $139,000 in 2003. This is primarily due to the increase in operating costs at the closed centers associated with implementing management's plan to close underperforming facilities and improve overall operations. These costs include the write-off of $214,000 in assets previously used in the operations of the closed centers, severance payments of $77,000 to 29 terminated employees, recognition of unexpired facility lease obligations of $253,000, and other associated costs. Gross profit for ongoing centers also declined $793,000, or 60.8%, from $1,304,000 to $511,000 in 2003. Most of this result was due to the loss of certain testing revenue of $220,000, a decrease in California platelet volume of $698,000, increases in insurance costs of $275,000 and the write-off of certain assets related to the Sherman Oaks facility totaling $186,000. 12 13 General and Administrative Expenses General and administrative expenses declined from 2003 to 2002 by $128,000, or 3.1%, to $3,946,000. This decline is most attributable to the elimination of any litigation expenses associated with the Company's claims against the ARC. During 2002, the Company paid $285,000 in legal expense associated with the ARC claim. Late in 2002, the Company and the ARC settled all of the outstanding issues between them. In addition, approximately $247,000 was incurred during 2002 for severance related expenses for the Company's former Chief Executive Officer. Offsetting these reductions in expense from 2003 to 2002 is $112,000 in increases in audit and tax preparation expenses. In addition, the Company incurred other costs in 2003, including insurance, that also reduced the beneficial effect from the elimination of some of the costs incurred in 2002. Income Taxes During 2003, the Company recorded a valuation allowance of $2,984,000 against deferred tax assets. This non-cash charge reduced the net value of the deferred tax assets on the balance sheet to zero. The assets were created as a result of income tax benefits that were recorded as a result of operating losses in prior years. Current accounting standards place significant weight on a history of recent cumulative losses in determining whether it is more likely than not that the Company will realize the tax benefits in the near future and accordingly whether a valuation allowance is necessary. Forecasts of future taxable income are not considered sufficient positive evidence to outweigh a history of losses. Accordingly, the assets were reserved in full. The Company's federal net operating loss carryforwards are not impacted by this change in valuation allowance and therefore are still available for future use for up to 20 years. Year ended December 31, 2002 compared to the Year ended December 31, 2001 - -------------------------------------------------------------------- Overview Revenues for 2002 were $27,817,000, compared to $25,199,000 in 2001. The increase of $2,618,000, or 10.4%, was due to opening several new blood centers and the expansion of the California mobile operations. These were partially offset by a decline in the overall demand for blood services in 2002. Gross profit was $3,745,000, or 13.5% of revenues, during 2002, compared to $4,409,000, or 17.5% of revenues, in 2001. The decline was primarily due to start-up losses incurred to open new blood centers and lower overall margins in whole blood collection programs. In 2002, the Company incurred a net loss of $591,000, or $0.08 per share basic and diluted, compared to net income of $323,000, or $0.04 per share basic and diluted, in 2001. The loss in 2002 included severance to the former Chief Executive Officer of $247,000, write-off of goodwill of $362,000, litigation expense with the ARC of $285,000 and start-up losses at our newly opened blood centers of $862,000. Revenue and Gross Profits Blood Products In mid-2001, the ARC announced a significant increase in its whole blood prices. Many hospitals concerned about rising costs and product availability began looking for alternative blood vendors. The Company responded to this opportunity by opening new blood centers and expanding the Southern California mobile whole blood collection capacity. Average revenue per red blood cell increased from $143 at the end of 2001 to $185 at the end of 2002. As a result of the increase in the prices of whole blood derived products, the Company substantially increased revenue from whole blood collection during 13 14 2002. This was especially apparent in the California mobile whole blood program. The following table summarizes the revenues, gross profit and units sold for both 2002 and 2001 for free standing blood centers and California mobile operations:
For the tweleve months period ended December 31, ($ in Thousands) Blood Centers California Mobiles Total ----------------- ------------------ ------------------ 2002 2001 2002 2001 2002 2001 -------- -------- -------- ------- -------- -------- Revenue.................... $13,602 $14,421 $ 5,842 $ 2,045 $19,444 $16,466 Gross Profit............... $ 848 $ 1,471 $ 149 $ 16 $ 997 $ 1,487 Gross Profit Margin........ 6% 10% 3% 1% 5% 9% Units Sold Single Donor Platelets.. 22,900 23,300 - - 22,900 23,300 Whole Blood............. 16,600 15,300 31,900 11,900 48,500 27,200 - ------------------
Blood Centers Revenue from blood centers decreased $819,000, or 5.7%, in 2002 compared with 2001. The decrease was primarily due to the closure of the St. Vincent's blood center in August 2001. This program provided revenue of $1,312,000 in 2001. Additionally, the Company collected fewer platelet products at the Sherman Oaks facility, and the donor center at Long Beach Memorial Medical Center was closed in August 2002. These decreases were partially offset by increased red cell prices in 2002. California Mobiles Revenues from the California mobile operations increased $3,797,000, or 186%, in 2002 compared with 2001. This growth was due to a higher volume of collections resulting from the expansion of the program in 2002, as well as from higher red blood cell prices in 2002. Gross profit on California mobile operations was $149,000, or 3% of revenue, in 2002, compared to a gross profit of $16,000, or 1% of revenue, in 2001. As a result of the mid-year price increases, this program became profitable during the second half of 2002. Blood Services Revenues from blood services were $8,373,000 in 2002, compared to $8,733,000 in 2001, a decrease of $360,000 or 4%. The Company experienced a decrease in demand for services in California, partially offset by an increase in demand in the East Coast market. The Company performed 7,140 therapeutic apheresis procedures in 2002 compared to 7,520 in 2001, and the revenue per procedure during this period remained basically unchanged. Gross profit was $2,748,000, or 33% of revenue in 2002, compared to $2,922,000, or 33% of revenue, in 2001. General and Administrative Expenses General and administrative expenses increased to $4,074,000, in 2002, compared to $3,918,000 in 2001, an increase of $156,000, or 4%. The increase reflects contractual severance to the former Chief Executive Officer of $247,000 and increased expenses related to the ARC litigation of $285,000 in 2002 compared to $110,000, in 2001. These increases were partially offset by the reduction of salary and other related expenses for the former President of West Coast Products, who resigned during the third quarter of 2001 and was not replaced. In 2002, general and administrative expenses decreased to 15% of revenue from 16%, in 2001. 14 15 Goodwill Impairment Charge During the third quarter of 2002, continued declines in the Company's stock price indicated that the goodwill associated with the acquisition of Coral Blood Services in 1998 may be impaired. Management completed an interim test for impairment during the third quarter and concluded that the existing goodwill was impaired. The Company recorded an adjustment to write-off all of the remaining goodwill in the amount of $362,000 during the third quarter. 2003 and 2002 Quarterly Financial Data - --------------------------------------- The Company generated positive net income of $264,000 in the fourth quarter of 2003, representing the largest net income in any single quarter in 2003 or 2002. Most of this positive result was due to improved gross profit margins at the remaining donor centers, and reduced overhead expenses required to support the organization. Fourth quarter results also included $50,000 in supplemental revenue as a result of a review of the pricing for prior period testing services to one of the Company's larger hospital customers. In addition, lease obligation adjustments associated with the closure of certain blood centers, resulted in a net benefit in the fourth quarter of $35,000. The following table presents unaudited statement of operations data for each of the eight quarters ended December 31, 2003. Management believes that all necessary adjustments have been included to fairly present the quarterly information when read in conjunction with the consolidated financial statements. The operating results for any quarter are not necessarily indicative of the results for any subsequent quarter. UNAUDITED (In Thousands, Except Per Share Data)
2003 2002 Quarter Ended Quarter Ended ------------------------------------- ------------------------------------- Mar 31 Jun 30 Sep 30 Dec 31 Mar 31 Jun 30 Sep 30 Dec 31 -------- -------- -------- -------- -------- -------- ------- -------- Revenues............. $ 6,931 $ 6,937 $ 6,980 $6,640 $ 6,321 $ 6,940 $ 7,181 $ 7,375 Gross Profit......... 942 378 (176) 1,107 910 987 1,022 826 Income (loss) before income taxes........ 14 (454) (1,519) 264 (219) (31) (527) 35 Income tax provision (benefit)........... 6 (182) 3,160 - (81) (12) (65) 7 -------- -------- -------- -------- -------- -------- -------- -------- Net income(loss)..... $ 8 $ (272) $(4,679) $ 264 $ (138) $ (19) $ (462) $ 28 ======== ======== ======== ======== ======== ======== ======== ======== Earnings (loss) per share Basic.............. $ - $ (0.04) $ (0.60) $ 0.04 $ (0.02) $ - $ (0.06) $ - Diluted............ $ - $ (0.04) $ (0.60) $ 0.04 $ (0.02) $ - $ (0.06) $ -
Critical Accounting Policies and Estimates - ------------------------------------------ General The Company's discussion and analysis of its financial condition and results of operations are based on the Company's consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and 15 16 liabilities. On an on-going basis, the Company evaluates its estimates, including those related to valuation reserves, income taxes and intangibles. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Allowance for Doubtful Accounts - ------------------------------- The Company makes ongoing estimates relating to the collectibility of accounts receivable and maintain a reserve for estimated losses resulting from the inability of customers to meet their financial obligations to the Company. In determining the amount of the reserve, management considers the historical level of credit losses and makes judgments about the creditworthiness of significant customers based on ongoing credit evaluations. Since management cannot predict future changes in the financial stability of customers, actual future losses from uncollectible accounts may differ from the estimates. If the financial condition of customers were to deteriorate, resulting in their inability to make payments, a larger reserve may be required. In the event it is determined that a smaller or larger reserve was appropriate, the Company would record a credit or a charge to general and administrative expense in the period in which such a determination is made. Income Taxes - ------------ As part of the process of preparing the financial statements, the Company is required to estimate income taxes in each of the jurisdictions that the Company operates. This process involves estimating actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included in the balance sheet. Management must then assess the likelihood that the deferred tax assets will be recovered from future taxable income, and to the extent management believes that recovery is not likely, must establish a valuation allowance. To the extent a valuation allowance is created or adjusted in a period, the Company must include an expense, or benefit, within the tax provision in the statements of operations. Significant management judgment is required in determining the provision for income taxes, deferred tax asset and liabilities and any valuation allowance recorded against net deferred tax assets. Management continually evaluates if the deferred tax asset is likely to be realized. If management determines that the deferred tax asset is not likely to be realized, a write-down of that asset would be required and would be reflected in the provision for taxes in the accompanying period. Goodwill - -------- During the first quarter of 2002, the Company adopted Statement of Financial Accounting Standards ("SFAS") No. 142, "Goodwill and Other Intangible Assets." In accordance with SFAS 142, the Company discontinued amortizing goodwill that was recorded as part of the Coral Blood Services, Inc. acquisition in 1998. During 2002, the Company determined that the goodwill was impaired and recorded an adjustment to write off all of the remaining goodwill in the amount of $362,000. The Company does not have any other intangible assets. During 2001 and prior, goodwill was amortized on a straight-line basis over ten years. Goodwill amortization was $53,000 for the year ended December 31, 2001. Liquidity and Capital Resources - ------------------------------- At December 31, 2003, the Company had cash and cash equivalents and marketable securities of $935,000 and working capital of $1,179,000. The Company has a working capital line of credit with Comerica Bank - California. The amount the Company may borrow is the lesser of 75% of eligible accounts receivable less amounts outstanding on the notes payable discussed below, or $2 million. Interest is payable monthly at a rate of prime plus 0.5% (4.50% as of December 31, 2003). As of 16 17 December 31, 2003, the Company's net borrowings on this line of credit were $450,000. This line of credit matures in June 2004, and is included in "current obligations under notes payable" on the balance sheet. As of December 31, 2003, the unused portion of the Company's line of credit was $1,363,000. This loan is collateralized by substantially all of the Company's asset and requires the maintenance of certain financial covenants, including minimum levels of profitability, quick assets to current liability ratio, debt to equity ratio and prohibits the payment of dividends or stock repurchases. As of December 31, 2003, the Company was not in compliance with all of these covenants. The Company requested, and Comerica agreed to waive these covenant violations. The Company also has various other notes payable with Comerica Bank - California that are secured by equipment. As of December 31, 2003, the total amount outstanding under these notes is $245,000 and requires monthly principal payments of approximately $14,000 plus interest at a weighted average fixed rate of 6.6%. All of the Comerica loans are collateralized by substantially all of the Company's assets and are cross-defaulted. In addition, the Company has another note payable with One Source Financial. As of December 31, 2003, the balance due on this note was $73,000. The note requires quarterly payments of approximately $10,000, including interest at the rate of 8.5%, and is secured by certain fixed assets. The Company also has a note payable related to financing certain insurance premiums. As of December 31, 2003, the balance due on this note was $65,000 and requires monthly payments of approximately $13,000, including interest at a rate of 3.4%. Finally, late in 2003, the Company completed an asset purchase transaction for blood collection and blood treatment equipment. The Company financed this transaction as a capital lease with the manufacturer. As of December 31, 2003, the total value of the lease obligation was $932,000, and requires monthly payments of approximately $18,000, which includes interest at a rate of 7.5%. The following table summarizes our contractual obligations by year (in thousands).
Payments due by year ---------------------------------------------------------------- Total 2004 2005 2006 2007 2008 Thereafter ------- ------- ------ ------ ------ ------ ---------- Operating leases.... $ 782 $ 304 $ 259 $ 215 $ 4 $ - $ - Capitalized leases.. 1,392 306 312 305 229 222 18 Long term debt...... 834 710 121 3 - - - ------- ------- ------ ------ ------ ------ ---------- Totals.............. $ 3,008 $ 1,320 $ 692 $ 523 $ 233 $ 222 $ 18 ======= ======= ====== ====== ====== ====== ==========
Previously, the Company was also committed to purchase approximately $14 million of blood collection kits at established prices through 2007. Late in 2003, the Company completed negotiations with the supplier of these kits to eliminate this commitment and reduce the price the Company pays for these kits. Net cash provided by operating activities was $761,000 for 2003, and $714,000 for 2002. The increase of $27,000 was due to efforts by management to increase cash collections which caused a decrease in net accounts receivable. Although the Company recorded a net loss of $4,679,000 during 2003, this was primarily offset by i) depreciation expense and amortization of $1,163,000, ii) increase in the deferred tax asset valuation allowance of $2,984,000, and iii) a decrease in accounts receivable of $1,495,000. The depreciation expense is mostly related to valuation adjustments associated with the implementation of management's plan to close facilities and improve overall operations. The increase in the deferred tax asset valuation reserve is due to management's estimate of the likelihood that the Company will utilize this asset against future taxable income. The decrease in accounts receivable is due to management's efforts to increase collections. During 2003, these efforts reduced the number of days sales outstanding to 42 compared with 62 days as of December 31, 2002. In addition to the above, management initiated efforts to pay suppliers within terms that caused a reduction in outstanding payables, and therefore utilized cash during 2003 of $801,000. 17 18 For 2003, net cash used in investing activities was $191,000 compared with $1,193,000 for all of 2002. The cash used in investing activities was primarily for the acquisition of plant and equipment. During 2002, the Company purchased a variety of new capital assets including mobile blood collection vehicles, a new blood banking computer system, laboratory equipment, and leasehold improvements for new facilities. During 2003, management's plan to close facilities and improve operations did not require any substantial investment in new capital assets. Cash used by financing activities in 2003 was $683,000 compared with $502,000 of cash provided by these activities in 2002. Most of the cash utilized in 2003 was to reduce outstanding debt, capitalized leases or other notes payable. The cash provided in 2002 was primarily from net borrowings associated with the acquisition of assets discussed previously. Management anticipates that cash on hand, availability on the bank line of credit and cash generated from operations will be sufficient to provide funding for any of the Company's needs during the next six months, including working capital requirements, equipment purchases and lease commitments. The Company has received written approval from Comerica Bank to extend the termination date of the existing line of credit into 2005. Based on this information, combined with the expected improvement in cash flow from the closure of the non- performing donor centers, the Company is expected to have sufficient cash resources to fund any of the Company's needs well into 2005. The Company's liquidity is dependent, in part, on timely collections of accounts receivable. Any significant delays in customer payments could adversely affect the Company's liquidity. Liquidity also depends on maintaining compliance with the various loan covenants and the extension or replacement of the Comerica line of credit. From time-to- time, the Company has failed to comply with the some of these covenants. The Company has obtained waivers from the bank involved for each covenant violation; however, if in the future the Company is unable to comply with a loan covenant and the bank does not agree to waive the violation, the bank could accelerate the payment obligations and severely reduce the Company's liquidity and available cash resources. Factors Affecting Forward-Looking Information - --------------------------------------------- The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" from liability for forward-looking statements. Certain information included in this Form 10-K and other materials filed or to be filed by the Company with the Securities and Exchange Commission (as well as information included in oral statements or other written statements made or to be made by or on behalf of the Company) are forward-looking, such as statements relating to operational and financing plans, competition, the impact of future price increases for blood products and demand for the Company's products and services. Such forward-looking statements involve important risks and uncertainties, many of which will be beyond the control of the Company. These risks and uncertainties could significantly affect anticipated results in the future, both short-term and long-term, and accordingly, such results may differ from those expressed in forward-looking statements made by or on behalf of the Company. These risks and uncertainties include, but are not limited to those listed below as "Risk Factors" or in other filings by the Company with the Securities and Exchange Commission. Risk Factors Affecting the Company - ---------------------------------- Short and long-term success is subject to many factors that are beyond management's control. Shareholders and prospective shareholders in the Company should consider carefully the following risk factors, in addition to other information contained in this report. This Annual Report on Form 10-K contains forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements as a result of various risks and uncertainties, including those described below. 18 19 Operating Risk The Company recently completed a plan to eliminate underperforming facilities to improve the profitability of the Company. The future of the Company now depends on generating sufficient operating profit from the remaining facilities to cover overhead expenses. The remaining facilities have not always been consistently profitable. Therefore, the Company is at risk if management is unable to execute an operating plan that will produce consistent profits from the remaining facilities. Potential Loss of Lines of Credit In December 2002, the Company replaced the then existing lines of credit with a new $2.0 million working capital line of credit that requires the Company maintain certain financial covenants including profitability each quarter. As of December 31, 2003, the Company was not in compliance with several covenants, including debt to equity ratios and liquidity ratios. The bank has waived these violations. Maintaining compliance is dependent, among other things, on achieving the required profitability. In 2002, the Company lost $591,000 and $4,679,000 in 2003. Continued losses would violate the terms of the new credit line. While in the past the bank granted covenant violation waivers when needed, the Company cannot assure that the bank will continue to grant waivers in the future. Failure to obtain such waivers when, and if needed, could result in acceleration of payment obligations under the credit agreement and severely reduce liquidity. In addition, the existing credit agreement expires June 30, 2004. Management will make efforts to replace this facility; however, the Company cannot assure that alternative financing will be available. Failure to replace this facility will adversely impact liquidity and could deprive the Company of the working capital needed to continue to operate. Potential Inability to Meet Future Capital Needs Currently, the Company believes it has sufficient cash available through its cash on hand, bank credit facilities and funds from operations to finance its operations for the next six months. However, the Company incurred a $4,679,000 loss during 2003. The Company may need to raise additional capital in the debt or equity markets. There can be no assurance that the Company will be able to obtain such financing on reasonable terms or at all. Additionally, there is no assurance that the Company will be able to obtain sufficient capital to finance future expansion. Market Prices for Blood Do Not Necessarily Reflect Costs The Company depends on competitive pricing to obtain and maintain sales. As costs increase, the Company may not be able to raise prices commensurately if competitors do not. Some competitors have greater resources than the Company to sustain periods of unprofitable sales. Cost increases may therefore have a direct negative effect on profits and a material adverse affect on the business. Declining Blood Donations The business depends on the availability of donated blood. Only a small percentage of the population donates blood, and new regulations intended to reduce the risk of introducing infectious diseases in the blood supply has decreased the pool of potential donors. If the level of donor participation in blood products declines, the Company may not be able to achieve profitability or reduce costs sufficiently to maintain profitability in blood products. Changes in California law have required the Company to cease its historical practice of compensating some of its apheresis platelet donors. While the Company has developed strategies to recruit volunteer donors, there can be no assurance that these strategies will result in sufficient collections to meet customer needs or to assure profitability. Increasing Costs The costs of collecting, processing and testing blood have risen significantly in recent years and will likely continue to increase. These cost increases are related to new and improved testing procedures to assure that blood is free of infectious disease, increased 19 20 regulatory requirements related to blood safety, and increased costs associated with recruiting blood donors. New testing protocols have required the Company to outsource much of the required testing. Competition, and in some cases multi-year contractual arrangements, may limit the Company's ability to pass these increased costs to customers. In this circumstance, the increased costs could reduce profitability and could have a material adverse effect on the business and results of operations. Impact of Reimbursement Rates Reimbursement rates for blood products and services provided to Medicaid and Medicare patients impact the fees that the Company is able to negotiate with hospitals. Decreases in reimbursement rates or increase which do not keep pace with higher costs, may impact the Company's profitability. Increasing Reliance on Outside Laboratories The Company maintains laboratories that are licensed and accredited to test blood products for purity, potency and quality. The Company also utilizes outside laboratories for a variety of tests. As other new testing and processing technologies are introduced, the Company has increased its reliance on outside laboratories. In using outside laboratories the Company will have less control over testing costs. In addition, because laboratory facilities competent in these new technologies are scarce, the loss of an outside laboratory because of competition for capacity would have a material adverse effect on the business. Targeted Donor Base Involves Higher Collection Costs Part of the Company's current operations involves conducting blood drives for organizations that provide a relatively small number of donors. Blood drives directed at smaller donor sites lack the efficiencies associated with larger blood drives. As a result, collection costs might be higher than the competition and may affect profitability and growth plans. Access to Insurance The Company currently maintains insurance coverage consistent with the industry; however, if the Company experiences losses or the risks associated with the blood products industry increase in the future, insurance may become more expensive or unavailable. The Company also cannot give assurance that as the business expands, or the Company introduces new products and services, that additional liability insurance on acceptable terms will be available, or that the existing insurance will provide adequate coverage against any and all potential claims. Also, the limitations on liability contained in various agreements and contracts may not be enforceable and may not otherwise protect the Company from liability for damages. The successful assertion of one or more large claims against the Company that exceeds available insurance coverage, or changes in insurance policies, such as premium increases or the imposition of large deductibles or co- insurance requirements, could materially and adversely affect the business. Not-For-Profit Status Gives Advantages to Our Competitors HemaCare Corporation is the only significant blood products supplier to hospitals in the U.S. that is operated for profit and investor owned. The not-for-profit competition is exempt from federal and state taxes, and has substantial community support and access to tax-exempt financing. The Company may not be able to continue to compete successfully with not-for-profit organizations and the business and results of operations may suffer material adverse harm. Potential Adverse Affect from Changes in the Healthcare Industry In the U.S., a fundamental change is occurring in the healthcare system. Competition to gain patients on the basis of price, quality and service is intensifying among healthcare providers who are under pressure to decrease the costs of healthcare delivery. A national 20 21 hospital chain has announced plans to sell 19 of its facilities in California, many of which are customers of the Company. In addition, there has been significant consolidation among healthcare providers as providers seek to enhance efficiencies, and this consolidation is expected to continue. As a result of these trends, the Company may be limited in its ability to increase prices for products in the future, even if costs increase. Further, the Company could be adversely affected by customer attrition as a result of consolidation or closure of hospital facilities. Future Technological Developments Could Jeopardize Business As a result of the risks posed by blood-borne diseases, many companies are currently seeking to develop synthetic substitutes for human blood products. HemaCare's business consists of collecting, processing and distributing human blood and blood products. The introduction and acceptance in the market of synthetic blood substitutes would cause material adverse harm to the business. Operations Depend on Obtaining the Services of Qualified Medical Professionals The Company is highly dependent upon obtaining the services of qualified medical professionals. In particular, operations depend on the services of registered nurses and other medical technolgists. Nationwide, the demand for these professionals exceeds the supply and competition for their services is strong. This shortage could be aggravated in the event of a war or other international conflict. If the Company is unable to attract and retain a staff of qualified medical professionals, operations would be adversely affected. Heavily Regulated Industry The business of collecting, processing and distributing blood and blood products are all subject to extensive and complex regulation by the state and federal governments. The Company is required to obtain and maintain numerous licenses in different legal jurisdictions regarding the safety of products, facilities and procedures, and regarding the purity and quality of blood products. In addition, state and federal laws include anti-kickback and self-referral prohibitions and other regulations that affect the relationships between blood banks, hospitals, physicians and other persons who refer business to each other. Health insurers and government payers, such as Medicare and Medicaid, also limit reimbursement for products and services, and require compliance with certain regulations before reimbursement will be made. The Company devotes substantial resources to complying with laws and regulations, and believes it is currently in compliance; however, the possibility cannot be eliminated that interpretations of existing laws and regulations will result in a finding that the Company has not complied with significant existing regulations. Such a finding could materially harm the business. Moreover, healthcare reform is continually under consideration by regulators, and the Company does not know how laws and regulations will change in the future. Some of these changes could require costly compliance efforts or expensive outsourcing of functions which could make some of the Company's operations prohibitively expensive or impossible to continue. Product Safety and Product Liability Blood products carry the risk of transmitting infectious diseases, including hepatitis, HIV and Creutzfeldt-Jakob Disease. HemaCare carefully screens donors, uses highly qualified testing service providers to test its blood products for known pathogens in accordance with industry standards, and complies with all applicable safety regulations. Nevertheless, the risk that screening and testing processes might fail or that new pathogens may be undetected by them cannot be completely eliminated. There is currently no test to detect the pathogen responsible for Creutzfeldt-Jakob Disease. If patients are infected by known or unknown pathogens, claims could exceed insurance coverage and materially and adversely affect the Company's financial condition. Furthermore, healthcare regulations are constantly changing and certain changes could require costly compliance or make some of our operations impossible to continue. 21 2 Environmental Risks HemaCare's operations involve the controlled use of bio-hazardous materials and chemicals. Although the Company believes that its safety procedures for handling and disposing of such materials comply with the standards prescribed by state and federal regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, the Company could be held liable for any damages that result, and any such liability could exceed the resources of the Company and its insurance coverage. The Company may incur substantial costs to maintain compliance with environmental regulations as it develops and expands its business. Business Interruption Due to Terrorism and Increased Security Measures In Response to Terrorism HemaCare's business depends on the free flow of products and services through the channels of commerce and freedom of movement for patients and donors. The 2001 response to terrorist activities slowed or stopped transportation, mail, financial and other services for a period of time. Further delays or stoppages in transportation of perishable blood products and interruptions of mail, financial or other services could have a material adverse effect on the Company's results of operations and financial condition. Furthermore, the Company may experience an increase in operating costs, such as costs for transportation, insurance and security, as a result of the terrorist activities and potential activities, which may target health care facilities or medical products. The Company may also experience delays in receiving payments from payers that have been affected by terrorist activities and potential activities. The U.S. economy in general is adversely affected by terrorist activities, and potential activities, and any economic downturn could adversely impact the Company's results of operations, impair its ability to raise capital or otherwise adversely affect its ability to grow its business. Articles of Incorporation and Rights Plan Could Delay or Prevent an Acquisition or Sale of HemaCare HemaCare's Articles of Incorporation empower the Board of Directors to establish and issue a class of preferred stock, and to determine the rights, preferences and privileges of the preferred stock. This gives the Board of Directors the ability to deter, discourage or make more difficult for a change in control of HemaCare, even if such a change in control would be in the interest of a significant number of shareholders or if such a change in control would provide shareholders with a substantial premium for their shares over the then-prevailing market price for our common stock. In addition, the Board of Directors has adopted a Shareholder's Rights Plan designed to require a person or group interested in acquiring a significant or controlling interest in HemaCare to negotiate with the Board. Under the terms of our Shareholders' Rights Plan, in general, if a person or group acquires more than 15% of the outstanding shares of common stock, all of the other shareholders would have the right to purchase securities from the Company at a discount to the fair market value of the common stock, causing substantial dilution to the acquiring person or group. The Shareholders' Rights Plan may inhibit a change in control and, therefore, could materially adversely affect the shareholders' ability to realize a premium over the then-prevailing market price for the common stock in connection with such a transaction. For a description of the Rights Plan see the Company's Current Report on Form 8-K filed with the SEC on March 5, 1998. Stocks Traded on the OTC Bulletin Board are Subject to Greater Market Risks than Those of Exchange-Traded and NASDAQ Stocks HemaCare's common stock was delisted from the NASDAQ Small Cap Market on October 29, 1998 because of the failure to maintain NASDAQ's requirement of a minimum bid price of $1.00. Since November 2, 1998, the common stock has traded on the OTC Bulletin Board, an electronic, screen-based trading system operated by the National Association of Securities Dealers, Inc. Securities traded on the OTC Bulletin Board are, for the most part, thinly traded and generally are not subject to the level of regulation imposed on securities listed or traded on the NASDAQ Stock Market or on a national securities exchange. As a result, an investor may find it difficult to dispose of our common stock or to obtain accurate quotations as to its price. 22 23 Stock Price Could Be Volatile The price of HemaCare's common stock has fluctuated in the past and may be more volatile in the future. Factors such as the announcements of government regulation, new products or services introduced by the Company or by the competition, healthcare legislation, trends in the health insurance, litigation, fluctuations in operating results and market conditions for healthcare stocks in general could have a significant impact on the future price of HemaCare's common stock. In addition, the stock market has from time to time experienced extreme price and volume fluctuations that may be unrelated to the operating performance of particular companies. The generally low volume of trading in HemaCare's common stock makes it more vulnerable to rapid changes in price in response to market conditions. Future Sales of Equity Securities Could Dilute the Company's Common Stock The Company may seek new financing in the future through the sale of its securities. Future sales of common stock or securities convertible into common stock could result in dilution of the common stock currently outstanding. In addition, the perceived risk of dilution may cause some shareholders to sell their shares, which could further reduce the market price of the common stock. Lack of Dividend Payments The Company intends to retain any future earnings for use in its business, and therefore does not anticipate declaring or paying any cash dividends in the foreseeable future. The declaration and payment of any cash dividends in the future will depend on the Company's earnings, financial condition, capital needs and other factors deemed relevant by the Board of Directors. In addition, the Company's credit agreement prohibits the payment of dividends during the term of the agreement. Item 7a Quantitative And Qualitative Disclosures About Market Risk - ------- ---------------------------------------------------------- In the normal course of business, the Company's operations are exposed to risks associated with fluctuations in interest rates. The Company manages its risks based on management's judgment of the appropriate trade-off between risk, opportunity and costs. Management does not believe that interest rate risks are material to the results of operations or cash flows of the Company, and, accordingly, does not generally enter into interest rate hedge instruments. The Company has $2,017,000 of debt, which includes $1,567,000 of notes payable and capitalized leases with fixed interest rates. The remaining $450,000 of debt represents advances on the working capital line of credit and the interest rate is linked to the prime interest rate. Accordingly, interest rate expense will fluctuate with rate changes in the U.S. If interest rates were to increase or decrease by 1% for the year, our interest expense would increase or decrease by approximately $4,500. Item 8 Financial Statements and Supplementary Data - ------ -------------------------------------------- The Index to Financial Statements and Schedules appears on page F-1, The Reports of Independent Public Accountants appears on F-2, F-3 and the Consolidated Financial Statements and Notes to Consolidated Financial Statements appear on pages F-4 to F-15. 23 24 Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosures - ------ ------------------------------------------------------------ The Company has not received the consent of Arthur Andersen LLP to the inclusion of its report of independent public accountants dated March 14, 2002 in the Company's Annual Report Form 10-K for the fiscal year ended December 31, 2002. Because Arthur Andersen LLP has not consented to the inclusion of their report into the Company;s Annual Report Form 10-K for the fiscal year ended December 31, 2002, you may not be able to recover against Arthur Andersen LLP for any untrue statements of a material fact contained in the financial statements or financial statement schedule audited by Arthur Andersen LLP or any omissions to state a material fact required to be stated therein. Item 9A Controls And Procedures - ------- ----------------------- The Chief Executive Officer and the Chief Financial Officer of the Company, with the participation of the Company's management, carried out an evaluation of the effectiveness of the Company's disclosure controls and procedures pursuant to Exchange Act Rule 13a-15(e). Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer believe that, as of the end of the period covered by this report, the Company's disclosure controls and procedures are effective in making known to them material information relating to the Company (including its consolidated subsidiaries) required to be included in this report. Disclosure controls and procedures, no matter how well designed and implemented, can provide only reasonable assurance of achieving an entity's disclosure objectives. The likelihood of achieving such objectives is affected by limitations inherent in disclosure controls and procedures. These include the fact that human judgment in decision- making can be faulty and that breakdowns in internal control can occur because of human failures such as simple errors or mistakes or intentional circumvention of the established process. There were no changes in the Company's internal controls over financial reporting, that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the Company's internal controls over financial reporting, known to the Chief Executive Officer or the Chief Financial Officer, subsequent to the date of the evaluation. PART III Item 10 Directors and Executive Officers of the Registrant - ------- -------------------------------------------------- The information concerning the directors and executive officers of the Company is incorporated here by reference from the section entitled "Proposal 1 - Election of Directors" contained in the definitive proxy statement of the Company to be filed pursuant to Regulation 14A within 120 days after the end of the Company's last fiscal year (the "Proxy Statement"). Item 11 Executive Compensation - ------- ---------------------- The information concerning executive compensation is incorporated herein by reference from the section entitled "Proposal 1 - Election of Directors" contained in the Proxy Statement. 24 25 Item 12 Security Ownership of Certain Beneficial Owners and Management and related stockholder matters - ------- --------------------------------------------------- The information concerning the security ownership of certain beneficial owners and management and related stockholder matters is incorporated herein by reference from the section entitled "General Information - Security Ownership of Principal Stockholders and Management" and "Proposal 1 - Election of Directors" contained in the Proxy Statement. Item 13 Certain Relationships And Related Transactions - ------- ---------------------------------------------- The information concerning certain relationships and related transactions is incorporated herein by reference from the section entitled "Proposal 1 - Election of Directors - Certain Relationships and Related Transactions" contained in the Proxy Statement. Item 14 Principal Accountant Fees and Services - ------- -------------------------------------- The information concerning the Company's principal accountant's fees and services is incorporated herein by reference from the section entitled "Independent Public Accountants" in the Proxy Statement. PART IV Item 15 Exhibits, Financial Statement Schedules and Reports on Form 8-K - ------- ------------------------------------------------------- The following are filed as part of this Report: (a) 1. Financial Statements An index to Financial Statements and Schedules appears on page F-1. 2. Financial Statement Schedules The schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission are not required under related instructions or are inapplicable, and therefore have been omitted. 3. Exhibits The following exhibits listed are filed or incorporated by reference as part of this Report. 3.1 Restated Articles of Incorporation of the Registrant incorporated by reference to Exhibit 3.1 to form 10-K of the Registrant for the year ended December 31, 2002, File No. 000-15233. 3.2 Amended and Restated Bylaws of the Registrant, as amended-- incorporated by reference to Exhibit 3.1.0 to Form 8-K of the Registrant dated February 19, 2003, File No. 000-15233. 4.1 Warrant Agreement between the Registrant and Alan C. Darlington, dated January 15, 2003--incorporated by reference to Exhibit 4.4 to form 10-K of the Registrant for the year ended December 31, 2002, File No. 000-15233. 25 26 4.2 Warrant Agreement between the Registrant and Alan C. Darlington, dated January 15, 2003--incorporated by reference to Exhibit 4.5 to form 10-K of the Registrant for the year ended December 31, 2002, File No. 000-15233. 4.3 Rights Agreement between the Registrant and U.S. Stock Transfer Corporation dated March 3, 1998--incorporated by reference to Exhibit 4 to Form 8-K of the Registrant dated March 5, 1998, File No. 000-15233. 4.4 Registration Rights of Shareholders--incorporated by reference to Exhibit 4.9 to the Current Report on Form 8-K of the Registrant dated August 19, 1996, File No. 000-15233. 10.1 1996 Stock Incentive Plan, as amended, of the Registrant-- incorporated by reference to Exhibit 4.1 to Form 10-Q of the Registrant for the quarter ended September 30, 1996, File No. 000-15233. 10.2 Loan and Security Agreement between the Registrant and Comerica Bank dated November 19, 2002--incorporated by reference to Exhibit 10.2 to form 10-K of the Registrant for the year ended December 31, 2002, File No. 000-15233. 10.3* Services Agreement between the Registrant and Alan C. Darlington, dated March 10, 1999--incorporated by reference to Exhibit 10.1 of Form 10-Q of the Registrant for the quarter ended March 31, 1999, File No. 000-15233. 10.4* Employment Agreement between the Registrant and Joshua Levy dated March 22, 2000--incorporated by reference to Exhibit 10.12 of Form 10-K of the Registrant for the year ended December 31, 2000, File No. 000-15233. 10.5* Employment Letter between the Registrant and Judi Irving, dated December 6, 2002--incorporated by reference to Exhibit 10.8 to form 10-K of the Registrant for the year ended December 31, 2002, File No. 000-15233. 10.6* Separation Agreement between the Registrant and Alan C. Darlington, dated September 28, 2002--incorporated by reference to Exhibit 10.9 to form 10-K of the Registrant for the year ended December 31, 2002, File No. 000-15233. 10.7 Master Security Lease Agreement between the Registrant and GE Capital Healthcare Financial Services dated December 26, 2002 --incorporated by reference to Exhibit 10.10 to form 10-K of the Registrant for the year ended December 31, 2002, File No. 000-15233. 10.8* Employment Letter between the Registrant and Robert S. Chilton, dated October 3, 2003--incorporated by reference to Exhibit 10.1 to form 10-Q of the Registrant for the quarter ended September 30, 2003, File No. 000-15233. 10.12 Lease Agreement between the Registrant and Gambro BCT, dated December 30, 2003. 11 Computation of earnings (loss) per common equivalent share. 21 Subsidiaries of the Registrant. 23.1 Consent of Ernst & Young LLP, Independent Auditors. 23.2 Notice Regarding Consent of Arthur Andersen LLP. 31.1 Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 26 27 31.2 Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1 Certification Pursuant to 18 U.S.C. 1350, Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. * Management contracts and compensatory plans and arrangements. (b) Reports on Form 8-K. The Company filed a Current Report on Form 8-K on November 4, 2004 disclosing under Item 5 (Other Information) the appointment Robert Chilton as Chief Financial Officer. SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: March 25, 2004 HEMACARE CORPORATION ------------------------ /s/ Robert S. Chilton -------------------------- Robert S. Chilton, Chief Financial Officer 27 28 Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant in the capacities indicated on the twenty-fifth day of March, 2004. Signature Title /s/ Julian L. Steffenhagen Chairman of the Board - ------------------------------ Julian L. Steffenhagen /s/ Judi Irving President and Chief Executive Judi Irving Officer and Director - ------------------------------- (Principal Executive Officer) /s/ Robert S. Chilton Executive Vice President and - ------------------------------- Chief Financial Officer Robert S. Chilton (Principal Financial and Accounting Officer) /s/ Steven Gerber Director - ------------------------------- Steven Gerber /s/ Robert L. Johnson Director - -------------------------------- Robert L. Johnson /s/ Terry Van Der Tuuk - -------------------------------- Terry Van Der Tuuk Director 28 F-1 Index to Consolidated Financial Statements and Schedules Item 14(a) (1) and (2)
Sequential Page Number ---------- Report of Independent Auditors Ernst & Young LLP......... F-2 Report of Independent Auditors Arthur Andersen, LLP...... F-3 Consolidated balance sheets at December 31, 2003 and December 31, 2002................................... F-4 For the years ended December 31, 2003, 2002 and 2001: Consolidated statements of operations............... F-5 Consolidated statements of shareholders' equity..... F-6 Consolidated statements of cash flows............... F-7 Notes to consolidated financial statements............... F-8
Other schedules are not submitted because either they are not applicable, not required or because the information required is included in the Consolidated Financial Statements, including the notes thereto. F-1 F-2 REPORT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS To the Stockholders of HemaCare Corporation: We have audited the accompanying consolidated balances sheet of HemaCare Corporation (a California corporation) and subsidiaries as of December 31, 2003 and 2002 and the related consolidated statements of operations, shareholders' equity and cash flows for each of the two years ended December 31, 2003. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits. The consolidated financial statements of HemaCare Corporation, for the fiscal year ended December 31, 2001, were audited by other auditors who have ceased operations. Those auditors expressed an unqualified opinion on those statements in their report dated March 14, 2002. We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of HemaCare Corporation and subsidiaries as of December 31, 2003 and 2002 and the consolidated results of their operations and their cash flows for each of the two years ended December 31, 2003 in conformity with accounting principles generally accepted in the United States. As discussed in Note 10 to the consolidated financial statements, HemaCare Corporation changed its method of accounting for purchased goodwill and other intangible assets in accordance with Statement of Financial Accounting Standards ("SFAS") No. 142 during the first quarter of fiscal 2002. As discussed above, the financial statements of HemaCare Corporation as of December 31, 2001, and for the year then ended were audited by other auditors who have ceased operations. As described in Note 10, these financial statements have been updated to include the transitional disclosures required by SFAS No. 142, "Goodwill and Other Intangible Assets," which was adopted by the Company as of January 1, 2002. Our audit procedures with respect to the disclosures in Note 10 for fiscal 2001 included (i) agreeing the previously reported net income to the previously issued financial statements and the adjustments to reported net loss representing amortization expense (including any related tax effects) recognized in those periods related to goodwill that are no longer being amortized to the Company's underlying records obtained from management, and (ii) testing the mathematical accuracy of the reconciliation of adjusted net loss to reported net income, and the related net earnings-per-share amounts. Our audit procedures with respect to the disclosures in Note 10 for fiscal 2001 included (i) agreeing the goodwill and amortization amounts and the gross intangible assets and accumulated amortization amounts to the Company's underlying records obtained from management, and (ii) testing the mathematical accuracy of the tables. In our opinion, the disclosures for fiscal 2001 in Note 10 related to the transitional disclosures of SFAS No. 142 are appropriate. However, we were not engaged to audit, review, or apply any procedures to the Company's financial statements for fiscal 2001 other than with respect to such disclosures and, accordingly, we do not express an opinion or any other form of assurance on the Company's fiscal 2001 financial statements taken as a whole. /s/ ERNST & YOUNG LLP Los Angeles, California February 17, 2004 F-2 F-3 This is a copy of the audit report previously issued by Arthur Andersen LLP in connection with HemaCare Corporation filing on Form 10-K for the year ended December 31, 2001. This audit report has not been reissued by Arthur Andersen LLP in connection with this filing on Form 10-K. See Exhibit 23.2 for further discussion. The consolidated balance sheet as of December 31, 2001, referred to in this report has not been included in the accompanying financial statements. REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS To the Stockholders of HemaCare Corporation: We have audited the accompanying consolidated balance sheets of HemaCare Corporation (a California corporation) and subsidiaries as of December 31, 2001 and 2000, and the related consolidated statements of operations, stockholders' equity and comprehensive income and cash flows for each of the three years in the period ended December 31, 2001. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of HemaCare Corporation, and subsidiaries as of December 31, 2001 and 2000 and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2001 in conformity with accounting principles generally accepted in the United States. /s/ ARTHUR ANDERSEN LLP Los Angeles, California March 14, 2002 F-3 F-4 HEMACARE CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS
December 31, December 31, 2003 2002 ------------- ------------ ASSETS Current assets: Cash and cash equivalents.................... $ 935,000 $ 1,048,000 Accounts receivable, net of allowance for doubtful accounts of $351,000 in 2003 and $208,000 in 2002............................ 3,128,000 4,932,000 Product inventories and supplies............. 494,000 795,000 Prepaid expenses............................. 388,000 295,000 Note receivable.............................. 20,000 - Deferred income taxes, current............... - 402,000 ------------- ------------- Total current assets................ 4,965,000 7,472,000 Plant and equipment, net of accumulated depreciation and amortization of $2,919,000 in 2003 and $2,450,000 in 2002.... 3,259,000 3,308,000 Deferred taxes................................. - 2,582,000 Other assets................................... 62,000 93,000 ------------- ------------- $ 8,286,000 $ 13,455,000 ============= ============= LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable............................. $ 1,686,000 $ 2,277,000 Accrued payroll and payroll taxes............ 918,000 1,231,000 Other accrued expenses....................... 243,000 201,000 Current obligations under capital leases..... 229,000 90,000 Current obligations under notes payable...... 710,000 199,000 ------------- ------------- Total current liabilities........... 3,786,000 3,998,000 Obligations under capital leases, net of current portion........................... 954,000 246,000 Notes payable, net of current portion.......... 124,000 1,107,000 Other long-term liabilities.................... 11,000 17,000 Commitments and contingencies (Note 12)........ Shareholders' equity: Common stock, no par value - 20,000,000 shares authorized, 7,756,060 issued and outstanding in 2003 and 7,751,090 in 2002.. 13,319,000 13,316,000 Accumulated deficit.......................... (9,908,000) (5,229,000) ------------- ------------- Total shareholders' equity.......... 3,411,000 8,087,000 ------------- ------------- $ 8,286,000 $ 13,455,000 ============= =============
The accompanying notes are an integral part of these consolidated financial statements. F-4 F-5 HEMACARE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Years Ended December 31
2003 2002 2001 ------------ ------------ ------------ Revenues: Blood products.................. $ 20,030,000 $ 19,444,000 $16,466,000 Blood services.................. 7,458,000 8,373,000 8,733,000 ------------- ------------- ------------ Total revenue................... 27,488,000 27,817,000 25,199,000 Operating costs and expenses: Blood products.................. 20,169,000 18,447,000 14,979,000 Blood services.................. 5,068,000 5,625,000 5,811,000 ------------- ------------- ------------ Total operating costs and expenses...................... 25,237,000 24,072,000 20,790,000 Gross profit.................... 2,251,000 3,745,000 4,409,000 General and administrative expenses. 3,946,000 4,074,000 3,918,000 ------------- ------------- ------------ Income (loss) from operations....... (1,695,000) (329,000) 491,000 Other income (expense).............. - (51,000) 22,000 Write off of impaired goodwill...... - (362,000) - ------------- ------------- ------------ Income (loss) before income taxes... (1,695,000) (742,000) 513,000 Provision (benefit) for income taxes............................ 2,984,000 (151,000) 190,000 ------------- ------------- ------------ Net income (loss).............. $ (4,679,000) $ (591,000) $ 323,000 ============= ============= ============ Income (loss) per share Basic.............................. $ (0.60) $ (0.08) $ 0.04 ============= ============= ============ Diluted............................ $ (0.60) $ (0.08) $ 0.04 ============= ============= ============ Weighted average shares outstanding - basic............................ 7,753,000 7,673,000 7,534,000 ============= ============= ============ Weighted average shares outstanding - diluted.......................... 7,753,000 7,673,000 8,298,000 ============= ============= ============
The accompanying notes are an integral part of these consolidated financial statements. F-5 F-6 HEMACARE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY For the Years Ended December 31, 2003, 2002 and 2001
Common Stock Accumulated Shares Amount Deficit Total --------- ------------ ------------ ------------- Balance as of December 31, 2000.. 7,690,000 $13,164,000 $(4,961,000) $ 8,203,000 Issuance of common stock for employee 401(k) and incentive bonus plans.............. 93,000 93,000 - 93,000 Stock repurchased... (332,000) (391,000) - (391,000) Stock options exercised.......... 140,000 199,000 - 199,000 Net Income.......... - - 323,000 323,000 ---------- ------------- ------------ ------------ Balance as of December 31, 2001.. 7,591,000 13,065,000 (4,638,000) 8,427,000 Issuance of common stock for employee 401(k) and incentive bonus plans.............. 76,000 122,000 - 122,000 Extension of stock options............ - 56,000 - 56,000 Warrants issued..... - 20,000 - 20,000 Stock options exercised.......... 84,000 53,000 - 53,000 Net Loss............ - - (591,000) (591,000) ---------- ------------- ------------ ------------ Balance as of December 31, 2002.. 7,751,000 13,316,000 (5,229,000) 8,087,000 Stock options exercised.......... 5,000 3,000 - 3,000 Net Loss............ - - (4,679,000) (4,679,000) ---------- ------------ ------------ ------------ Balance as of December 31, 2003.. 7,756,000 $13,319,000 $(9,908,000) $ 3,411,000 ========== ============ ============ ============
The accompanying notes are an integral part of these consolidated financial statements. F-6 F-7 HEMACARE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENT OF CASH FLOWS For the Years Ended DEcember 31
2003 2002 2001 ------------ ------------ ------------- Cash flows from operating activities: Net income (loss)............................... $(4,679,000) $ (591,000) $ 323,000 Adjustments to reconcile net income to net cash provided by (used in) operating activities: Provision for bad debts...................... 309,000 - 10,000 Use (recognition) of deferred tax assets..... 2,984,000 (81,000) 190,000 Depreciation and amortization................ 717,000 426,000 299,000 Gain (loss) on disposal of assets............ (11,000) (1,000) 2,000 Impairment of assets......................... 446,000 - - Impairment of goodwill....................... - 362,000 - Issuance of common stock and options for compensation................................ - 178,000 93,000 Changes in operating assets and liabilities: Decrease (increase) in accounts receivable... 1,495,000 522,000 (1,468,000) Decrease (increase) in inventories, supplies and prepaid expenses........................ 338,000 (191,000) 11,000 Decrease (increase) in other assets.......... 31,000 (2,000) (57,000) (Decrease) increase in accounts payable, accrued expenses, and other liabilities..... (801,000) 99,000 505,000 Other........................................ (68,000) (7,000) (1,000) ------------ ------------ ------------ Net cash provided by (used in) operating activities.................................. 761,000 714,000 (93,000) Cash flows from investing activities: Proceeds from sale of plant and equipment....... 79,000 10,000 - Decrease in marketable securities............... - - 868,000 Purchase of plant and equipment................. (270,000) (1,203,000) (1,646,000) ------------ ------------ ------------ Net cash used in investing activities.......... (191,000) (1,193,000) (778,000) Cash flows from financing activities: Proceeds from exercise of stock options......... 3,000 53,000 199,000 Repurchase and retirmenet of common stock....... - - (391,000) Principal payments on debts and and capitalized leases............................. (686,000) (258,000) (116,000) Other debt borrowings........................... - 132,000 - Borrowings on line of credit.................... - 575,000 842,000 ------------ ------------ ------------ Net cash provided by (used in) financing activities.................................... (683,000) 502,000 534,000 (Decrease) increase in cash and cash equivalents.................................... (113,000) 23,000 (337,000) Cash and cash equivalents at beginning of period........................................ 1,048,000 1,025,000 1,362,000 ------------ ------------ ------------ Cash and cash equivalents at end of period...... $ 935,000 $ 1,048,000 $ 1,025,000 ============ ============ ============ Supplemental disclosure: Interest paid................................... $ 79,000 $ 59,000 $ 30,000 ============ ============ ============= Income taxes paid............................... $ 18,000 $ - $ 44,000 ============ ============ ============ Items not impacting cash flows: Purchase of equipment - Capital lease........... $ 932,000 $ 162,000 $ 151,000 ============ ============ ============ Purchase of equipment - Notes................... $ - $ 30,000 $ - ============ ============ ============ Issuance of warrants............................ $ - $ 20,000 $ - ============ ============ ============ Insurance premiums financed..................... $ 130,000 $ - $ - ============ ============ ============
The accompanying notes are an integral part of these consolidated financial statements. F-7 F-8 HemaCare Corporation Notes to Consolidated Financial Statements December 31, 2003 Note 1 - Organization - --------------------- HemaCare Corporation is in the business of providing blood products and blood services to hospitals and medical centers primarily in California. Note 2 - Summary of Accounting Policies - --------------------------------------- Principles of Consolidation: The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents: The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial Instruments: Cash and cash equivalents, marketable securities, accounts receivable and accounts payable are carried at cost which approximates fair value. The interest rate applied to capital leases is based upon the Company's borrowing rate, and therefore their carrying value approximates fair value. Revenues and Accounts Receivable: Revenues are recognized upon acceptance of the blood products or the performance of blood services. Blood services revenues consist primarily of mobile therapeutics sales, while blood products revenues consist primarily of sales of single donor platelets and whole blood components that are manufactured or purchased and distributed by the Company and donor testing. Accounts receivable are reviewed periodically for collectibility. Inventories and Supplies: Inventories consist of Company-manufactured platelets and whole blood components as well as component blood products purchased for resale. Supplies consist primarily of medical supplies used to collect and manufacture products and to provide therapeutic services. Inventories are stated at the lower of cost of market and are accounted for on a first-in, first-out basis. Inventories are comprised of the following as of December 31, Inventories 2003 2004 ---------- ---------- Blood products $ 61,000 $ 126,000 Supplies $ 433,000 $ 669,000 ---------- ---------- $ 494,000 $ 795,000 ========== ========== Plant and Equipment: Plant and equipment are stated at original cost. Furniture, fixtures, equipment and vehicles are depreciated using the straight-line method over two to nine years. Leasehold improvements are amortized over the lesser of their useful life or the length of the lease, ranging from three to five years. The cost of normal repairs and maintenance are expensed as incurred. F-8 F-9 Goodwill: During the first quarter of 2002, the Company adopted Statement of Financial Accounting Standards ("SFAS") No. 142, "Goodwill and Other Intangible Assets." In accordance with SFAS 142, the Company discontinued amortizing goodwill. During 2002, the Company determined that the goodwill was impaired and recorded an adjustment to write off all of the remaining goodwill in the amount of $362,000. The Company does not have any other intangible assets. During 2001 and prior, goodwill was amortized on a straight-line basis over ten years. Goodwill amortization was $53,000 for the year ended December 31, 2001. Long lived Assets: All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets. Income Taxes: Income taxes are computed under the provisions of Statement of Financial Accounting Standards ("SFAS") No. 109, "Accounting for Income Taxes." SFAS 109 provides for an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. In estimating future tax consequences, SFAS 109 generally considers all expected future events other than enactments of changes in the tax law or rates. In 2003, the Company determined that it was more likely than not that the deferred tax assets on the balance sheet would not be used against future possible income. Therefore, the Company recorded a valuation reserve equivalent to 100% of the value of the available deferred tax assets. This resulted in a current period charge to the provision for income taxes of $2,984,000 in 2003. Per Share Data: Earnings per share-basic is computed by dividing net income by the weighted average shares outstanding. Earnings per share- diluted is computed by dividing net income by the weighted average number of shares outstanding including the diluted effect of options and warrants. Interest expense: During the three years ended December 31, 2002, 2001 and 2000 the Company incurred interest expense of $79,000, $61,000 and $30,000, respectively. Employee stock option plan: The Company accounts for its employee stock option plan under the recognition and measurement principles of Accounting Principles Board Opinion ("APB") No. 25, "Accounting for Stock Issued to Employees," and related Interpretations. Under APB No. 25, no stock-based compensation is reflected in net income, as all options granted under the plans had an exercise price equal to the market value of the underlying common stock on the date of grant and the related number of shares granted is fixed at that point in time. Reclassification: Certain prior year amounts have been reclassified to conform to the current year presentation. Recent accounting pronouncements: In April 2002, Statement of Financial Accounting Standards No. 145, Rescission of FASB Statements No. 4, 44 and 64, Amendment of FASB Statement 13, and Technical Corrections (SFAS No. 145) was issued and will be effective for fiscal years beginning after May 15, 2002. SFAS 145 eliminates the classification of debt extinguishment activity as extraordinary items, and provides corrections or clarifications of other existing authoritative pronouncements. The Company has elected early adoption and implemented the provisions of SFAS 145 during 2002, which did not have a material effect on the Company's consolidated financial statements. The FASB has issued FASB Statement No. 146 ("SFAS 146"), Accounting for Exit or Disposal Activities. SFAS 146 addresses the recognition, measurement, and reporting of costs that are associated with exit and disposal activities, including costs related to terminating a contract that is not a capital lease and termination benefits that employees who are involuntarily terminated receive under the terms of a one-time benefit arrangement that is not an ongoing benefit arrangement or an individual deferred-compensation contract. SFAS 146 supersedes Emerging Issues Task Force Issue No. 94-3, Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring) and requires F-9 F-10 liabilities associated with exit and disposal activities to be expensed as incurred. During 2003, the Company did close certain blood center operations, and applied SFAS 146 to recognize expenses associated with these closures as incurred. See Note 15. In November 2002, the Financial Accounting Standards Board issued Interpretation No. 45, Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others, (FIN 45). FIN 45 elaborates on the existing disclosure requirements for most guarantees. FIN 45 requires that at the time a company issues certain guarantees, the company must recognize an initial liability for the fair value, or market value, of the obligations it assumes under that guarantee and must disclose that information in its interim and annual financial statements. The initial recognition and initial measurement provisions of FIN 45 are applicable on a prospective basis to guarantees issued or modified after December 31, 2002. FIN 45's disclosure requirements are effective for financial statements of interim or annual periods ending after December 15, 2002 and are applicable to all guarantees issued by the guarantor subject to FIN 45's scope, including guarantees issued prior to the issuance of FIN 45. The Company adopted the provisions of FIN 45 in December 2002. The adoption did not have any material impact on the Company's consolidated financial statements. In December 2002, the FASB issued SFAS No. 148, "Accounting for Stock- Based Compensation-Transition and Disclosure -- An Amendment of SFAS No. 123" ("SFAS 148"). SFAS 148 provides alternative methods of transition for a voluntary change to the fair value-based method of accounting for stock-based employee compensation. The Company has accounted for its stock-based compensation to employees using the intrinsic methodology and provided the "disclosures only" information related to the fair value method as allowed under SFAS No. 123. SFAS 148 amends the disclosure requirements of SFAS No. 123 to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results. The Company has concluded it is in compliance with these required prominent disclosures. Note 3 - Plant and Equipment - ---------------------------- Plant and equipment consists of the following:
December 31, ------------------------ 2003 2002 ----------- ------------ Furniture, fixtures and equipment $ 5,704,000 $ 5,274,000 Leasehold improvements 474,000 484,000 ------------ ------------ 6,178,000 5,758,000 Less accumulated depreciation and amortization (2,919,000) (2,450,000) ------------ ------------ $ 3,259,000 $ 3,308,000 ============ ============
Depreciation expense for 2003, 2002 and 2001 was $717,000, $426,000 and $247,000, respectively. Note 4 - Line of Credit and Notes Payable - ----------------------------------------- The Company has a working capital line of credit with Comerica Bank - California. The amount the Company may borrow is the lesser of 75% of eligible accounts receivable less amounts outstanding on the notes payable discussed below, or $2 million. Interest is payable monthly at a rate of prime plus 0.5% (4.50% as of December 31, 2003). As of December 31, 2003, the Company's net borrowings on this line of credit were $450,000. This line of credit matures in June 2004, and is included in "current obligations under notes payable" on the balance sheet. As of December 31, 2003, the unused portion of the Company's line of credit was $1,363,000. F-10 F-11 This loan is collateralized by substantially all of the Company's assets and requires the maintenance of certain financial covenants, including minimum levels of profitability, quick assets to current liability ratio, debt to equity ratio and prohibits the payment of dividends or stock repurchases. As of December 31, 2003, the Company was not in compliance with all of these covenants. The Company has requested, and Comerica has agreed to waive these covenant violations. The Company also has various other notes payable with Comerica Bank - California that are secured by equipment. As of December 31, 2003, the total amount outstanding under these notes is $245,000 and requires monthly principal payments of approximately $14,000 plus interest at a weighted average fixed rate of 6.6%. The Company incurred interest expense to Comerica Bank in 2003, 2002 and 2001 of $47,000, $36,000 and $19,000 respectively. As of December 31, 2002, the Company was in compliance with these loan covenants. All of the Comerica loans are collateralized by substantially all of the Company's assets and are cross-defaulted. In addition, the Company has another note payable with One Source Financial. As of December 31, 2003, the balance due on this note was $73,000. The note requires quarterly payments of approximately $10,000 including interest at the rate of 8.5% and is secured by certain fixed assets. The Company also has a note payable related to financing certain insurance premiums. As of December 31, 2003, the balance due on this note was $65,000 and requires monthly payments of approximately $13,000 including interest at a rate of 3.4%. Future maturities under these notes are as follows: 2004 $ 710,000 2005 121,000 2006 3,000 ----------- $ 834,000 =========== Note 5 - Leases - --------------- The Company has entered into various capital leases for equipment, expiring on various dates through 2006. Included in property and equipment are the following assets held under capital leases. Year Ended December 31 2003 2002 ----------- ----------- Equipment $1,317,000 $ 439,000 Accumulated Depreciation (107,000) (92,000) ----------- ----------- $1,210,000 $ 347,000 =========== =========== Late in 2003, the Company completed an asset purchase transaction for blood collection and blood treatment equipment. The Company financed this transaction as a capital lease with the manufacturer. As of December 31, 2003, the total value of the lease obligation was $932,000, and requires monthly payments of approximately $18,000, which includes interest at a rate of 7.5%. F-11 F-12 The Company leases its facilities and certain equipment under operating leases that expire through the year 2009. Future minimum rentals under capitalized and operating leases are as follows: Year ending December 31 Capital Operating ----------- ----------- 2004..................... $ 306,000 $ 304,000 2005..................... 312,000 259,000 2006..................... 305,000 215,000 2007..................... 229,000 4,000 2008..................... 222,000 - 2009..................... 18,000 - ----------- ----------- Total: 1,392,000 $ 782,000 Less: Interest.......... (209,000) =========== ----------- Principal value.......... 1,183,000 Less: Current portion... (229,000) ----------- $ 954,000 =========== Total rent expense under all operating leases was $971,000, $796,000 and $517,000 for the years ended December 31, 2003, 2002 and 2001, respectively. Most of the operating leases for facilities include options to renew the lease at the then current fair market value for periods of one to five years. Additionally, the Company's facility in Sherman Oaks is currently operating under a month-to-month basis while contract negotiations are ongoing. In most cases, management expects that in the normal course of business, leases will be renewed or replaced by other leases. Note 6 - Severance - ------------------ During 2002, the Company's President and Chief Executive Officer left the Company. In accordance with the terms of his employment contract, he was entitled to severance in the amount of $247,000. This amount is being paid over a period of one year from the date of separation. As of December 31, 2003, the unpaid severance was $50,000. Pursuant to the terms of his employment contract, he previously received an option to purchase up to 250,000 shares of the Company's Common Stock at a price of $0.41 per share. In 2001, the former Chief Executive Officer was granted stock options to purchase 100,000 shares of the Company's Common Stock at the market price on the date of grant $1.20, subject to certain vesting requirements. All of the 250,000 stock options issued pursuant to the employment agreement and 20,000 stock options from the 2001 option grant were vested as of his separation date. In partial consideration for canceling these options, the former Chief Executive Officer received 250,000 warrants to purchase shares of the Company's Common Stock at $0.60 per share. Additionally, he received 20,000 warrants to purchase shares of the Company's Common Stock at $1.20 per share. All warrants have four-year lives. If the former Chief Executive Officer decided to purchase these warrants, the severance would be reduced by $20,000, which was approximately equal to the fair market value on the date of grant. During 2003, the former Chief Executive Officer did purchase the warrants in question, and his severance was reduced by $20,000. During 2002, the Company also extended the stock options to a former officer and accounted for the difference between the fair market value on the date of the extension and the exercise price as additional compensation in the amount of $56,000. This was accounted for in general and administrative expenses as employee compensation in 2002. F-12 F-13 Note 7 - Income Taxes - --------------------- The Provision (benefit) for income taxes for the years ended December 31, 2003, 2002 and 2001 is as follows: ----------- ---------- ------------ 2003 2002 2001 ----------- ---------- ------------ Current taxes: Federal................. $ - $ - $ 5,000 State................... 2,000 (50,000) 12,000 ----------- ---------- ------------ 2,000 (50,000) 17,000 Deferred taxes: Federal................. 2,647,000 (87,000) 146,000 State................... 335,000 (14,000) 27,000 ----------- ---------- ------------ 2,982,000 (101,000) 173,000 ----------- ---------- ------------ Provision (benefit) for income taxes......... $2,984,000 $(151,000) $ 190,000 =========== ========== ============ Differences between the provision (benefit) for income taxes and income taxes at statutory federal income tax rate for the years ended December 31, 2003, 2002 and 2001 are as follows: ------------ ---------- ------------ 2003 2002 2001 ------------ ---------- ------------ Income tax expense at fed- eral statutory rate...... $ (576,000) $ (250,000) $ 174,000 State income taxes, net of federal benefit...... (18,000) (5,000) 30,000 Change in valuation allowance............... 3,540,000 142,000 - Permanent differences..... 9,000 14,000 34,000 Other..................... 29,000 (52,000) (48,000) ------------ ---------- ----------- Income tax expense (benefit)................ $(2,984,000) $ (151,000) $ 190,000 ============ =========== =========== The Company has recorded a net deferred tax asset of $0 and $2,984,000 at December 31, 2003 and 2002, respectively. The components of the net deferred tax asset at December 31, 2003 and 2002 are as follows: 2003 2002 ----------- ----------- Current: Reserve................... $ 80,000 $ 108,000 Accrued expenses and other.................... 238,000 294,000 ----------- ----------- Total deferred tax assets................... $ 318,000 $ 402,000 Noncurrent: Net operating loss....... 2,825,000 2,016,000 Depreciation and amortization............ (15,000) 245,000 Tax credit carryforward.. 844,000 866,000 Other.................... 110,000 (3,000) Valuation allowance...... (4,082,000) (542,000) ----------- ----------- $ (318,000) $2,582,000 ----------- ----------- $ 0 $2,984,000 =========== =========== A valuation allowance is recorded if the weight of available evidence suggests it is more likely than not that some portion or all of the deferred tax asset will not be recognized. The Company determined in the third quarter of 2003 that, based on recent historical and expected future operating results, that it is more likely than not that the Company will not be able to realize a significant portion of its deferred tax assets. Therefore, the Company recorded a 100% valuation reserve against all of the deferred tax assets. F-13 F-14 At December 31, 2003, the Company had net operating loss carryforwards available for Federal income and state tax purposes totaling $9,662,000, which expires through 2012. At December 31, 2003, the Company had federal income tax credit carryforwards of approximately $528,000 expiring through 2010, and state tax credit carryforwards of approximately $789,000, which are not subject to expiration through 2010. Acquisitions of common stock which result in changes in equity ownership in the Company could result in an "ownership change" within the meaning of Section 382 of the Internal Revenue Code of 1986, as amended (the 'Code"), thereby imposing an annual limitation (the "Section 382 Limitation") on the Company's ability to utilize its net operating loss carryforwards to reduce future taxable income. In the event of a Section 382 Limitation, the Company's utilization of its net operating loss carryforwards would be restricted. Note 8 - Shareholders' Equity - ----------------------------- Stock Options In July 1996, the Company's Board of Directors approved and adopted a stock incentive plan, which provides for grants of both stock options and shares of restricted stock. A total of 2,000,000 shares may be granted under the terms of the 1996 Plan. The term of the options granted is determined by the Company's Board of Directors, but in no event may be longer than ten years. The exercise price of options granted generally is required to be not less than the fair market value of the common stock on the date of grant. Options granted to employees generally vest at a rate of at least 20% per year. The table below summarizes stock option transactions.
2003 2002 2001 ------------------ ----------------- ------------------ Shares Price Shares Price Shares Price ---------- -------- ---------- ------ --------- ------- Outstanding at beginning of year................. 1,264,000 $0.96 1,521,000 $0.92 1,365,000 $0.86 Granted.................. 330,000 $ .74 400,000 $0.70 345,000 $1.32 Exercised................ (5,000) ($0.63) (84,000) ($0.63) (140,000) ($1.42) Canceled................. (210,000) ($1.06) (573,000) ($0.66) (49,000) ($1.04) ---------- ---------- ---------- Outstanding at end of year................. 1,379,000 $0.91 1,264,000 $0.96 1,521,000 $0.92 ========== ========== ========== Exercisable at end of year................. 915,000 $0.95 703,000 $1.04 939,000 $0.80 ========== ========== ==========
The following table summarizes the range of exercise price, weighted average remaining contractual life ("Life") and weighted average exercise price ("Price") for all stock options outstanding as of December 31, 2003:
Options Outstanding Options Exercisable ------------------------------- -------------------- Range of Exercise Price Shares Life Price Shares Price - ------------------------- ----------- --------- -------- ---------- -------- $0.32 to $0.75 724,000 5.5 years $ 0.53 534,000 $ 0.58 $0.76 to $1.50 520,000 8.0 years $ 1.04 272,000 $ 1.12 $1.51 to $2.44 135,000 5.5 years $ 2.29 109,000 $ 2.31 --------- ------ --------- ------ 1,379,000 $ 0.91 915,000 $ 0.95 ========= ====== ========= ======
The Company has elected to adopt SFAS 123 "Accounting for Stock-Based Compensation" for disclosure purposes only and applies the provisions of APB Opinion No. 25. The Company did not recognize any compensation expense related to the issuance of stock options in 2003, 2002 or 2001. Had compensation expense for all options granted to employees been recognized in accordance with SFAS 123, the Company's net income and net income per share would have been as follows: F-14 F-15
Years ended December 31, 2003 2002 2001 ------------ --------- ---------- Net income (loss) as reported........ $(4,679,000) $(591,000) $ 323,000 Pro forma net income (loss)...... $(4,753,000) $(728,000) $ 171,000 Basic income (loss) per share as reported........... $ (0.60) $ (0.08) $ 0.04 Diluted income (loss) per share as reported....... $ (0.60) $ (0.08) $ 0.04 Pro forma basic net income (loss) per share.............. $ (0.61) $ (0.09) $ 0.02 Pro forma diluted net income (loss) per share.......... $ (0.61) $ (0.09) $ 0.02
The above pro forma amounts were calculated by estimating the fair value of each option or warrant granted on the date of grant using the Black-Scholes option-pricing model as follows:
Years ended December 31, 2003 2002 2001 ---------- --------- ---------- Expected life....... 4 Years 4 Years 4 Years Expected volatility. 113% 113% 40% Interest rate....... 3.6% 3.6% 6.2% Dividend yield...... 0% 0% 0%
Warrants At December 31, 2003, 2002 and 2001, the Company had a total of 270,000, 760,000 and 520,000 warrants to purchase common stock outstanding, at weighted average exercise prices of $0.64, $3.23 and $4.60, respectively. All of the warrants outstanding for all periods were exercisable. The weighted average lives for warrants outstanding at December 31, 2003 is 2.75 years. As part of the severance with the former Chief Executive Officer (see Note 6 - Severance), the Company cancelled 350,000 stock options with a weighted average exercise price of $0.64 per share. The Company issued 270,000 warrants to the former Chief Executive Officer with an average exercise price of $0.64 per share. These warrants are fully vested and expire in 2006. Stock Repurchase In 2000, the Company announced its intention to repurchase up to 15% of its outstanding common stock, or up to 1.1 million shares. Purchases were made in the open market or in private transactions depending on price and availability. In 2000, the Company purchased 439,558 shares at an average price of $1.58 per share. In 2001, the Company purchased 332,300 shares at an average price of $1.18 per share. No purchases were made in 2002 or 2003, and the Company has terminated this program. Note 9 - Earnings per Share - --------------------------- The following table provides the calculation methodology for the numerator and denominator for earnings per share: F-15 F-16
Years Ended December 31, 2003 2002 2001 ------------ ----------- ------------ Net income (loss)...... $(4,679,000) $ (591,000) $ 323,000 Shares outstanding..... 7,753,000 7,673,000 7,534,000 Net effect of diluted options and warrants.. - - 764,000 ------------ ----------- ------------ Dilutive shares oustanding............ 7,753,000 7,673,000 8,298,000 ============ =========== ============ Earnings (loss) per share dilutled........ $ (0.60) $ (0.08) $ 0.04 ============ =========== ============
Warrants and options to purchase 1,649,000 and 2,024,000 shares of common stock at December 31, 2003 and 2002 respectively, were excluded from the 2003 and 2002 computation of diluted earnings per share because the Company incurred a loss in these years. They were anti- dilutive. Warrants and options to purchase 590,000 shares of common stock at December 31, 2001, were excluded in the computation of diluted earnings per share because the exercise price of the warrants and options was greater than the average market price of the common stock. Note 10 - Goodwill - ------------------ During 2002, the Company adopted Statement of Financial Accounting Standards Number 142, "Goodwill and Other Intangible Assets," (SFAS 142). In accordance with SFAS 142, the Company discontinued amortizing goodwill that was recorded as part of the acquisition. As of December 31, 2001, the Company had $530,000 of goodwill and accumulated amortization of $168,000. During 2002, management determined that the goodwill was impaired and recorded an adjustment to write-off all of the remaining goodwill in the amount of $362,000. The Company does not have any other intangible assets other than goodwill. The following table presents net income (loss) on a comparable basis after adjustment for amortization of goodwill:
2003 2002 2001 ------------ ------------ ------------ Reported net income (loss)... $(4,679,000) $ (591,000) $ 323,000 Goodwill amortization, net of taxes................ - - 31,000 Goodwill impairment, net of taxes................ - 217,000 - ------------ ------------- ----------- Adjusted net income (loss)... $(4,679,000) $ (374,000) $ 354,000 ============ ============ =========== Income (loss) per share Basic Reported net income (loss).. $ (0.60) $ (0.08) $ 0.04 Goodwill amortization....... - - 0.00 Goodwill impairment......... - 0.03 - ------------ ----------- ------------ Adjusted net income (loss).. $ (0.60) $ (0.05) $ 0.04 ============ =========== ============ Diluted Reported net income (loss).. $ (0.60) $ (0.08) $ 0.04 Goodwill amortization....... - - 0.00 Goodwill impairment......... - 0.03 - ------------ ----------- ------------ Adjusted net income (loss).. $ (0.60) $ (0.05) $ 0.04 ============ =========== ============
F-16 F-17 Note 11 - 401(k) Profit Sharing Plan - ------------------------------------- HemaCare's 401(k) Profit Sharing Plan (the "401(k) Plan") qualifies, in form, under Section 401(k) of the Internal Revenue Code (the "401(k) Plan"). For 2001 and 2000, the Company elected to match 50 percent of each participant's contribution, up to 5% of the participants' annual salary, with HemaCare common stock. During 2002 and 2001, HemaCare issued 76,365 shares ($122,000) and 92,848 shares ($93,000) of common stock as matching contributions for the 2001 and 2000 plan years, respectively. For the 2002 plan year, the Company contributed cash in the amount of $124,000 in 2003 as matching contributions. The Company did not make any contributions to the 401(k) Plan in 2003 pertaining to the 2003 plan year. Note 12 - Commitments and Contingencies - --------------------------------------- Since 1976, California law has prohibited the infusion of blood products into patients if the donors of those products were paid unless, in the opinion of the recipient's physician, blood from a non- paid donor was not immediately available. Apheresis platelet products obtained from paid donors, including the Company's Sherman Oaks Center's paid donors, were exempted from this law by a series of state statutes, which, expired on January 1, 2003. Effective January 2, 2003, the Company only accepts platelet donations from volunteer donors. During 2003, 2002 and 2001 revenues from apheresis platelet donors were $4,100,000, $5,374,000 and $5,956,000 respectively. State and federal laws set forth anti-kickback and self-referral prohibitions and otherwise regulate financial relationships between blood banks and hospitals, physicians and other persons who refer business to them. While the Company believes its present operations comply with applicable regulations, there can be no assurance that future legislation or rule making, or the interpretation of existing laws and regulations will not prohibit or adversely impact the delivery by HemaCare of its services and products. Healthcare reform is continuously under consideration by lawmakers, and it is not certain as to what changes may be made in the future regarding health care policies. However, policies regarding reimbursement, universal health insurance and managed competition may materially impact the Company's operations. The Company is also party to various claims, actions and proceedings incidental to its normal business operations. The Company believes the outcome of such claims, actions and proceedings, individually and in the aggregate, will not have a material adverse effect on the business and financial condition of the Company. The Company entered into a long-term commitment with a vendor to purchase kits used to produce blood products from blood donors and to provide blood services to patients. Under the terms of the agreement, the Company was obligated to purchase $10 million of kits at established prices through July 2006. During 2003, the Company renegotiated the terms of this purchase agreement to eliminate the kit commitment entirely. Note 13 - Segment Information - ----------------------------- The Company operates in two business segments as follows: - - Blood Products: Collection, processing and distribution of blood products and donor testing. - - Blood Services: Therapeutic apheresis and stem cell collection procedures and other therapeutic services provided to patients. Management uses more than one criterion to measure segment performance. However, the dominant measurements are consistent with the Company's consolidated financial statements which present revenue from external customers and operating profit income for each segment. Supplemental data are as follows: F-17 F-18
Blood Products Blood Services -------------- -------------- 2003 Depreciation and amortization $ 918,000 $ 51,000 Expenditures for fixed assets 828,000 291,000 2002 Depreciation and amortization $ 226,000 $ 19,000 Expenditures for fixed assets 1,300,000 - 2001 Depreciation and amortization $ 109,000 $ 27,000 Expenditures for fixed assets 1,097,000 145,000
Management evaluates segment performance based primarily on operating income. Other revenue and expenses are not allocated to the segments. The accounting policies of the segments are the same as those described in the significant accounting policies. Note 14 - Allowance for Doubtful Accounts - ----------------------------------------- Increases to the allowance for doubtful accounts totaled $309,000, $0 and $10,000 for the years ended December 31, 2003, 2002 and 2001, respectively. Write-offs against the allowance for doubtful accounts totaled $165,000, $4,000 and $2,000 for the years ended December 31, 2003, 2002 and 2001, respectively. Note 15 - Exit and Disposal Activities - -------------------------------------- As the result of an evaluation of the overall operations of the Company, management implemented a plan to cease operations at several donor centers, including the mobile operations associated with these centers beginning in the third quarter of 2003. The donor centers included in this plan were Albany, New York; Chicago, Illinois; three centers in North Carolina; and Williston Vermont. As of December 31, 2003, all of these donor centers were closed with the exception of the donor center in Chapel Hill, North Carolina, which was closed in January 2004. Costs associated with the closures are reflected in the Company's 2003's results in accordance with generally accepted accounting principals. As a result of the implementation of management's plan to close certain locations as described above, the Company's blood products segment incurred or anticipates will incur certain expenses associated with closing these centers. These expenses included the write-off of $214,000 of certain assets previously used in the operations of the closed donor centers, severance payments of $77,000 to 29 terminated employees, recognition of unexpired facility lease obligations of $253,000, and other associated costs. F-18 F-19 The following represents a reconciliation of the provision created in the blood products business segment as a result of the closure of these centers:
Remaining Accrual as of December 31, Provision Utilized 2003 --------- --------- ------------ Termination Benefits: $ 77,000 $ 76,000 $ 1,000 Lease Abandonment Costs: 253,000 253,000 0 Fixed Asset Write-down: 214,000 214,000 0 Other Costs: 54,000 28,000 26,000 --------- --------- ------------ Total: $ 598,000 $ 571,000 $ 27,000 ========= ========= ============
All of these expenses were incurred in 2003. Of the $598,000 provision recorded in 2003, $571,000 and $27,000 was recorded as operating expenses and general and administrative expenses, respectively. Note 16 - Subsequent Events - --------------------------- In February 2004, the Company received notice from Gambro BCT ("Gambro"), one of the Company's largest suppliers, that the California Board of Equalization was conducting an audit of Gambro's sales tax records. Gambro communicated to the Company that preliminary results of this audit indicated that the Company is likely to receive a refund of previously paid sales taxes. The amount of the potential refund has not yet been determined; however, preliminary indications are that the amount could be material. The Company will record the benefit of this refund as soon as the amount can be reasonably estimated and is certain. F-19 EXHIBIT INDEX
10.12 Lease Agreement between the Registrant and Gambro BCT, dated December 30, 2003. 11 Computation of earnings (loss) per common equivalent share. 21 Subsidiaries of the Registrant. 23.1 Consent of Ernst & Young LLP, Independent Auditors. 23.2 Notice Regarding Consent of Arthur Andersen LLP. 31.1 Certification Pursuant to Rule 13-a-14(a) of the Securities Exchange Act of 1934, Adopted Pursuant to Section 302 of the Sabanes-Oxley Act of 2002. 31.2 Certification Pursuant to Rule 13-a-14(a) of the Securities Exchange Act of 1934, Adopted Pursuant to Section 302 of the Sabanes-Oxley Act of 2002. 32.1 Certification Pursuant to 18 U.S.C. 1350 Adopted Pursuant to Section 906 fo the Sarbanes Oxley Act of 2002.
EX-10 3 ex1012g.txt LEASE AGREEMENT BETWEEN THE REGISTRANT AND GAMBRO BCT EXHIBIT 10.12 HemaCare Corporation Lease (Installment Sale) Agreement December 30, 2003 GAMBRO BCT December 30, 2003 LEASE (INSTALLMENT SALE) AGREEMENT COBE(R) Spectra(TM) Apheresis System/Trima(TM) Automated Blood Collection System Gambro BCT, Inc., 10811 W. Collins Avenue, Lakewood, CO 80215- 4440 ("Company"), hereby agrees to sell to HemaCare Corporation, 21101 Oxnard Street, Woodland Hills, CA 91367, ("Customer") and Customer hereby agrees to lease the equipment ("Equipment") identified below, subject to the following terms and conditions: 1. TERM OF AGREEMENT The term of this Agreement shall begin thirty days after the date the Equipment is shipped by Company to the Customer's location and, unless sooner terminated shall continue for thereafter for the term stated on Exhibit A. 2. PAYMENTS (a) Lease Payments. Customer shall pay Company the monthly lease charges in equal monthly installments, as stated in Exhibit A, for the duration of the term of this Agreement. Each monthly lease payment is due within thirty (30) days of Company's invoice date. Customer shall submit a valid purchase order for the total monthly lease billings covering the full term of the Agreement. (b) Purchase Option. Subject to Customer's compliance with its obligations under this Agreement, Customer shall have the option to purchase the Equipment for an exercise price calculated as set forth in Exhibit "B" to this Agreement. Customer must give thirty (30) days prior written notice to Company and pay the full exercise price plus all amounts otherwise due and payable under this Agreement within such thirty (30) day period. Should early termination of this Agreement occur pursuant to Paragraph 14, or should Customer be in default of any of its obligations arising hereunder, this option shall be null and void. See Exhibit B for an amortization schedule for the purchase option. (c) Terms of Payment. All monthly lease installment payments and any other payments by Customer under this Agreement shall be made at Company's "remit to" address as set forth on Company's invoices. Company shall have the right to charge Customer interest at the rate of one and one-half percent (1-1/2%) per month (or the maximum rate permitted by law, whichever may be less) on any lease installment billing or other billing under this Agreement which is not paid when due. 3. DELIVERY OF PRODUCT All Company product (equipment and disposable products) shall be shipped and delivered to Customer F.O.B. Shipping Point, via surface transportation, at the address specified in the first paragraph of this Agreement. Freight and handling charges are prepaid and added to the invoice. 4. LIMITED WARRANTY Company will replace or, at its option, repair (free of charge) for the original purchaser any part of new Equipment which is defective in materials or workmanship during the first 12 months of the term of this Agreement (during the first 6 months for refurbished Equipment). This limited warranty does not include replacement or repair of any part which fails because of misuse, accident, neglect, failure to use and maintain the Equipment in accordance with instructions of Company, as set forth in the Operator's Manual, or alterations by unauthorized persons. THIS LIMITED WARRANTY IS EXPRESSLY IN LIEU OF ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. GAMBRO 2 WILL NOT BE LIABLE FOR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT OR THE CUSTOMER'S USE OF THE EQUIPMENT. Repairs required as a result of abuse or misuse of the Equipment, as determined by Company in good faith, will be charged to the Customer. To request service, Customer should call the Service Response Center at (800) 525-2623 and provide the Name, Model Number and Serial Number of the Equipment. 5. INSTRUCTION Company will complete the in-service programmed training of two or three of the Customer's employees in the use of the Equipment and Disposable Products. Should there be changes in the contracted Equipment or its use or the Disposable Products with the Equipment, Company agrees to provide additional instruction as reasonably necessary for Customer's employees to properly utilize the Equipment and Disposable Products. 6. MAINTENANCE (a) In conjunction with the execution of an Agreement, a Company-approved equipment maintenance and service program must be undertaken to commence at the end of the warranty period and remain in effect for the term of the Agreement. (b) Customer will operate the Equipment in accordance with the instructions given in the ("Gambro") Operator's Manual for the Equipment and will perform all cleaning and maintenance procedures set forth in the Manual. 7. LOSS OR DAMAGE Customer shall bear the entire risk of loss, theft, destruction or damage of or to the Equipment (herein "loss") from any cause other than the negligence of Company, whether or not covered by insurance, and no such loss shall release Customer from its obligations under this Agreement, including Customer's obligation to pay the monthly lease installment payments for the term of this Agreement. In the event of loss, Customer shall repair the Equipment or, if not repairable, shall either replace the Equipment with another ("Gambro") equipment unit of equal quality or provide Company with such substitute security for performance of its obligations hereunder as Company may reasonably require. 8. INSURANCE Customer shall provide and maintain, at its own cost and expense, insurance for the Equipment against loss, theft, damage, or destruction in an amount not less than the stipulated value, as stated below, naming Company as an additional insured, and provide Company with such evidence of this insurance as Company may reasonably require. STIPULATED VALUES DURING TERM: (Per Instrument) SPECTRA STIPULATED VALUES DURING TERM (Per Instrument): First 12 Months $51,350 Second 12 Months $46,729 Third 12 Months $42,523 Thereafter $38,696 TRIMA STIPULATED VALUES DURING TERM (Per Instrument): First 12 Months $57,680 Second 12 Months $52,489 Third 12 Months $47,765 Thereafter $43,466 9. NONASSIGNABILITY BY CUSTOMER Without Company's prior written consent, Customer shall not (a) assign, transfer or otherwise dispose of the Equipment, and its rights and obligations under this Agreement, or (b) sublet or lend the Equipment or permit it to be used by anyone other than Customer, Customer's employees, or authorized personnel using the Equipment under Customer's supervision. 3 10. TAXES Customer agrees to pay promptly any and all applicable taxes, assessments, or other charges levied or assessed on or with respect to acquisition, possession, or use of the Equipment, or reimburse Company in the event Company has paid such taxes. 11. GOVERNMENT REGULATIONS Customer shall comply with all governmental statutes, ordinances and regulations relating to possession or use of the Equipment and indemnify Company against all liability and expense (including attorney fees) arising from Customer's failure to do so. 12. SURRENDER-RETURN Upon termination of this Agreement for any reason other than Customer's full payment of the lease price, or if Company should rightfully demand possession of the Equipment, the Customer shall immediately return the Equipment to Company, at Customer's expense, and to the extent permitted by applicable law, Company shall have the right to enter the Customer's premises to take possession of the Equipment. The return packaging and shipping expenses shall be paid by Customer, in addition to the cost to refurbish the Equipment. The Equipment when returned to Company shall be in as good condition as when delivered to Customer, ordinary wear and tear excepted. 13. TITLE Title to the Equipment shall remain at all times in Company. Customer shall attach to, and shall not remove from, the Equipment all labels provided by Company identifying the Equipment as belonging to Company. Upon Customer's exercise of the Purchase Option set forth in Section 2 (b) and full payment of the exercise price and all amounts due hereunder, or upon completion of payment of the monthly Lease Payments set forth in Section 2 (a) and all amounts due hereunder, Company shall promptly convey title in the Equipment to Customer. 14. SECURITY INTEREST Customer grants to Company a security interest in the Equipment to the extent of Customer's interest therein and any proceeds therefrom to secure Customer's payment of the monthly lease installment payments for the term of this Agreement and Customer's performance of its obligations under this Agreement. Customer agrees that it will not sell, transfer, or encumber the Equipment or any interest therein and will, upon demand, execute and deliver to Company such financing statements and other documents and will do all such acts and things as Company may reasonably request or as may be necessary or appropriate to establish and maintain a valid security interest in the Equipment and proceeds therefrom, subject to no prior liens or encumbrances. Upon Customer's default in payment of any installment payment or performance of any of its other obligations arising under this Agreement (such default not having previously been cured as otherwise provided herein), Company at its option may declare all monthly lease installment payments to be immediately due and payable and shall then have the remedies of a secured party under the Uniform Commercial Code or other applicable law. Expenses of retaking, holding, preparing for sale, selling, including Company's reasonable attorney's fees and expenses shall be paid by Customer. The security interest created hereby shall survive any termination of this Agreement by Company pursuant to Paragraph 15 below. Customer hereby authorizes Company or its agents or assigns to execute and file on its behalf any and all necessary Uniform Commercial Code filings to perfect the security interest granted herein. 15. DEFAULT Company may terminate this Agreement upon written notice to Customer if Customer remains in breach of the terms of this Agreement fifteen (15) days following written notice of such breach. In addition, Company may immediately terminate this Agreement upon written notice to the Customer of nonpayment of a monthly lease installment payment or other amounts due under this Agreement, or upon Customer's dissolution, insolvency, receivership, assignment for the benefit of creditors, or bankruptcy. 4 Upon termination of this Agreement, all of Customer's rights under this Agreement shall absolutely terminate, but Customer shall remain liable for the remaining monthly lease payments and any other amounts which may have accrued during the term of this Agreement. 16. ATTORNEY FEES Customer agrees to pay all reasonable attorney fees and expenses Company may incur in enforcing its security interest in the Equipment or in recovering amounts owed to Company under this Agreement. 17. NOTICES AND DEMANDS All notices required or permitted under this Agreement shall be delivered in person, by telecopy or by certified mail, return receipt requested, postage prepaid, to the party receiving notice at the party's address stated in this Agreement, or to such other address as the party to receive notice may specify to the other party by written notice pursuant to the paragraph. Notices shall be effective on personal delivery on receipt of the telecopy or on the third business day following the date of mailing. 18. ENTIRE AGREEMENT This Agreement constitutes the final, complete and exclusive expression and statement of the terms of the agreement between the parties. In case of any conflict between the terms and conditions of this Agreement and any order, confirmation, acknowledgment or correspondence pertaining to the subject matter hereof, the terms and conditions of this Agreement shall govern and no change, modification, addition in the terms and conditions of this Agreement shall be binding on Company or Customer unless such change has been expressly agreed to in writing by the parties hereto. 19. MISCELLANEOUS This Agreement shall be governed by Colorado law. No representations, warranties or agreements, oral or written, express or implied, have been made by either party with respect to this Agreement. Compliance with the terms of this Agreement may only be waived in a writing signed by the party waiving compliance with such terms. Should any provision of this Agreement be found by a court to be unenforceable or invalid, this Agreement shall be construed as if the unenforceable or invalid provision were omitted. This Agreement is binding upon the legal representatives and successors in interest of the parties hereto. 20. ACCEPTANCE OF AGREEMENT This Agreement must be signed and returned with your confirming purchase order (which does not contain any other terms and conditions) by January 16, 2004; after which date, this Agreement becomes null and void. Gambro BCT, Inc. HemaCare Corporation - -------------------------- --------------------------------- Customer: Full Corporate Name /s/ Barbara Zahlen /s/ Judi Irving - -------------------------- --------------------------------- Signature Signature Barbara Zahlen Judi Irving - -------------------------- --------------------------------- Name (Typed or Printed) Name (Typed or Printed) Contract Administrator CEO - -------------------------- --------------------------------- Title Title December 3, 2003 December 30, 2003 - -------------------------- ---------------------------------- Date Date ---------------------------------- FEI # bz 5 EXHIBIT A LEASE AGREEMENT PURCHASE DESCRIPTION OF EQUIPMENT QPP and Usage Equipment listed below is currently at customer sites under the previous Quantity Purchase Program Agreement (QPP) and is now transferred to this new Lease Installment Sale Agreement. QPP Equipment currently under the Agreement at HemaCare sites: Equipment Serial/Lot Numbers - ------------------------------------ -------------------------------- COBE SPECTRA(TM) Apheresis System 3086 - ---------------------------------------------------------------------- Trima Collection System 1T00177, 1T00178, 1T00179, 1T00180 - ---------------------------------------------------------------------- QPP Equipment currently under the Agreement at Coral Blood Services Sites: Equipment Serial/Lot Numbers - ------------------------------------ --------------------------------- COBE SPECTRA(TM) Apheresis System 4037, 2862, 2963 - ----------------------------------------------------------------------- Single-Needle Return Flow Controller 1396 - ----------------------------------------------------------------------- Spectra Seal Safe 2268 - ----------------------------------------------------------------------- SpectraTHERM(TM) Blood/Fluid Warmer 1232, 1400, 1399 - ----------------------------------------------------------------------- Trima(TM) System 1T00404, 1T00615, 1T00621, 1T00623, 1T00838, 1T00839, 1T00915 - ----------------------------------------------------------------------- Trima Seal Safe 0083, 0211, 0181, 0212, 0333, 0344, 0391 - ----------------------------------------------------------------------- Usage Equipment currently under the Agreement at HemaCare sites (Title remains with Gambro BCT): Equipment Serial/Lot Numbers - ---------------------------------- ----------------------------------- COBE SPECTRA(TM) Apheresis System 2138, 2139, 4544, 4549, 4552 - ------------------------------------------------------------------------ Usage Equipment currently under the Agreement at Coral Blood Services Sites (Title remains with Gambro BCT): Equipment Serial/Lot Numbers - ---------------------------------- ----------------------------------- COBE SPECTRA(TM) Apheresis System 963, 630 - ------------------------------------------------------------------------ Equipment to be added to this Lease Installment Sale Agreement: (The equipment listed below is currently at Coral Blood Services sites and was NOT included in the previous QPP Agreement.)
Catalog Description Quantity Serial Number # - ----------- ----------------------- -------- ----------------------------- 917-000-000 Trima Collection System 8 1T01179, 1T01178, 1T01175, 1T01181, 1T01304, 1T01302, 1T01338, 1T01572 - ------------------------------------------------------------------------------ 917-100-000 Trima Seal Safe 8 0521, 0513, 0519, 0512, 0587, 0541, 0672, 0914 - ------------------------------------------------------------------------------
6 SCHEDULE A: EQUIPMENT AND DISPOSABLES (continued) Disposable Products - Pricing is firm for 12 months from date of signature on this Agreement.
Spectra Disposable Products: Catalog # Product Code Description Price/Procedure - --------- ------------ ------------------------------------ --------------- CPT1003 70500 Therapeutic Plasma Exchange (TPE) $106.00 Set, 6/case - ------------------------------------------------------------------------------- CPT1005 777-006-000 White Blood Cell (WBC) Removal $106.00 Set, 6/case - ------------------------------------------------------------------------------- CPT1007 70700 Red Blood Cell (RBC) Exchange Set, $140.00 6/case - ------------------------------------------------------------------------------- CPT1112 777-003-015 Dual Needle (DN) Extended Life $120.00 Platelet (ELP) Set w/LRS Chamber, 6/case - ------------------------------------------------------------------------------- CPT1119 777-003-215 Single Needle (SN) Extended Life $120.00 Platelet (ELP) Set w/LRS Chamber, 6/case - -------------------------------------------------------------------------------
Trima Disposable Products:
Catalog # Product Code Description Price/Procedure - --------- ------------ ------------------------------------ --------------- CPT1081 777-800-100 Trima RBC, Platelet, Plasma Set, $140.00 6/case - ------------------------------------------------------------------------------- CPT1280 777-800-150 Trima RBC, Platelet, Plasma +TLR $158.00 filter, 6/case - ------------------------------------------------------------------------------- CPT1182 777-800-200 Trima RBC Plasma Set, 6/case $60.00 - ------------------------------------------------------------------------------- CPT1282 777-800-250 Trima Plasma, RBC +TLR filters, $100.00 6/case - ------------------------------------------------------------------------------- CPT1340 777-800-400 Trima Accel RBC, Platelet, $166.00 Plasma, 6/case - ------------------------------------------------------------------------------- CPT1345 777-800-450 Trima Accel RBC, Platelet, Plasma $184.00 w/TLR filter, 6/case - ------------------------------------------------------------------------------- CPT1350 777-800-500 Trima Accel RBC/Plasma, 6/case $60.00 - ------------------------------------------------------------------------------- CPT1355 777-800-550 Trima Accel RBC/Plasma w/TLR $100.00 filter, 6/case - -------------------------------------------------------------------------------
TERM: 60 Months MONTHLY LEASE INSTALLMENT PRICE: $17,083.32 EX-11 4 ex11ye.txt COMPUTATION OF EARNINGS (LOSS) PER COMMON EQUIVALENT SHARE HEMACARE CORPORATION EXHIBIT 11 BASIC AND DILUTED NET INCOME PER SHARE
Year ended December 31, 2003 2002 ----------- ----------- BASIC Weighted average common shares used to compute basic earnings per share 7,753,000 7,673,000 ============ =========== Net loss $(4,679,000) $ (591,000) ============ =========== Basic net loss per share $ (0.60) $ (0.08) ============ =========== DILUTED Weighted average common shares used to compute basic earnings per share 7,753,000 7,673,000 Dilutive common equivalent shares attributable to stock options (based on average market price) 226,000 - Dilutive common equivalent shares attributable to warrants (based on average market price) 55,000 - Weighted average common shares and equivalents used to compute diluted earnings per share 8,034,000 7,673,000 ============ =========== Net loss $(4,679,000) $ (591,000) ============ =========== Diluted net loss per share $ (0.58) $ (0.08) =========== ===========
EX-21 5 ex21sub.txt SUBSIDIARIES OF THE REGISTRANT EXHIBIT 21 Subsidiaries of the Registrant Coral Blood Services, Inc. HemaBiologics, Inc. Comprehensive Blood Services, Inc. EX-23.1 6 ex231ey.txt CONSENT FROM ERNST & YOUNG, LLP EXHIBIT 23.1 CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS We consent to the incorporation by reference in the Registration Statements on Form S-8 pertaining to the 1996 Stock Incentive Plan (No.333-18601.), the 1986 Stock Option Plan (No. 33-60101 and No. 33-52622) of HemaCare Corporation our report dated February 17, 2004, with respect to the consolidated financial statements of HemaCare Corporation included in the Annual Report (Form 10-K) for the year ended December 31, 2003. /s/ ERNST & YOUNG LLP Los Angeles, California March 22, 2004 EX-23.2 7 ex232con.txt NOTICE REGARDING CONSENT OF ARTHUR ANDERSEN LLP Exhibit 23.2 NOTICE REGARDING CONSENT OF ARTHUR ANDERSEN LLP Section 11(a) of the Securities Act of 1933, as amended (the "Securities Act"), provides that if any part of a registration statement at the time such part becomes effective contains an untrue statement of a material fact or an omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, any person acquiring a security pursuant to such registration statement (unless it is proved that at the time of such acquisition such person knew of such untruth or omission) may sue, among others, every accountant who has consented to be named as having prepared or certified any part of the registration statement, or as having prepared or certified any report or valuation which is used in connection with the registration statement, with respect to the statement in such registration statement, report or valuation which purports to have been prepared or certified by the accountant. As previously disclosed in the HemaCare Corporation's form 8-K filed on June 27, 2002, HemaCare Corporation dismissed Arthur Andersen LLP as its independent public accountants and announced that the Company had appointed Ernst & Young LLP to replace Arthur Andersen LLP as its independent public accountants. HemaCare's understanding is that the staff of the Securities and Exchange Commission has taken the position that it will not accept consents from Arthur Andersen LLP if the engagement partner and the manager for the HemaCare Corporation audit are no longer with Arthur Andersen LLP. Both the engagement partner and the manager for the HemaCare Corporation audit are no longer with Arthur Andersen LLP. As a result, HemaCare has been unable to obtain Arthur Andersen LLP's written consent to the incorporation by reference into the Registration Statements of its audit report with respect to the Company's financial statements as of December 31, 2001 and 2000 for the years then ended. Under these circumstances, Rule 437a under the Securities Act permits HemaCare Corporation to file this Form 10-K without a written consent from Arthur Andersen LLP. As a result, however, Arthur Andersen LLP will not have any liability under Section 11(a) of the Securities Act for any untrue statements of a material fact contained in the financial statements audited by Arthur Andersen LLP or any omissions of a material fact required to be stated therein. Accordingly, you would be unable to assert a claim against Arthur Andersen LLP under Section 11(a) of the Securities Act for any purchases of securities under the Registration Statements made on or after the date of this Form 10-K. To the extent provided in Section 11(b)(3)(C) of the Securities Act, however, other persons who are liable under Section 11(a) of the Securities Act, including the Company's officers and directors, may still rely on Arthur Andersen LLP's original audit reports as being made by an expert for purposes of establishing a due diligence defense under Section 11(b) of the Securities Act. EX-31.1 8 ex311ji.txt CERTIFICATION FROM JUDI IRVING, CEO CERTIFICATION I, Judi Irving certify that: 1. I have reviewed this annual report on Form 10-K of HemaCare Corporation. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report; 3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in the annual report: 4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15b-14) for the registrant and we have: a. designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared; b. evaluated the effectiveness of the registrant's disclosure controls and procedure as of a date within 90 days prior to the filing date of this annual report (the "Evaluation Date"); and c. presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date; 5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function): a. all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and 6. The registrant's other certifying officers and I have indicated in this annual report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses. Date: March 24, 2004 /s/ Judi Irving - --------------------------- Judi Irving Chief Executive Officer EX-31.2 9 ex312rc.txt CERTIFICATION FROM ROBERT CHILTON, CFO CERTIFICATION I, Robert S. Chilton certify that: 1. I have reviewed this annual report on Form 10-K of HemaCare Corporation. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report; 3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in the annual report: 4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15b-14) for the registrant and we have: a. designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared; b. evaluated the effectiveness of the registrant's disclosure controls and procedure as of a date within 90 days prior to the filing date of this annual report (the "Evaluation Date"); and c. presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date; 5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function): a. all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and 6. The registrant's other certifying officers and I have indicated in this annual report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses. Date: March 25, 2004 /S/ Robert S. Chilton - ----------------------------- Robert S. Chilton Chief Financial Officer EX-32 10 ex32cer.txt CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002 EXHIBIT 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. 1350 ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 10-K for the year period ended December 31, 2003 of HemaCare Corporation (the "Company") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such periodic report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in such report. Very truly yours, /s/ Judi Irving - -------------------------------- Judi Irving Chief Executive Officer /s/ Rober S. Chilton - -------------------------------- Robert S. Chilton Chief Financial Officer Dated: March 25, 2004 -----END PRIVACY-ENHANCED MESSAGE-----